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Streptococcus pneumoniae is a leading cause of pneumonia, meningitis and 
bacteremia worldwide. The 23-valent pneumococcal polysaccharide vaccine 
(PPV23) is recommended for adults less than 65 years old with certain chronic 
medical conditions and for all elderly persons because of high rates of invasive 
pneumococcal infections (IPI) and increased risk of death. This study provides 
a comprehensive picture of the epidemiology of pneumococcal infections in 
Finland before the introduction of childhood pneumococcal conjugate vaccines, 
focusing on disease rates, risk factors, clinical outcome, and healthcare associ-
ated infections.
The true incidence of IPI in Finland may be higher than previously reported. In 
working age adults, two-thirds of severe infections and one half of fatal cases oc-
cured in persons with no recognized PPV23 indication. Persons with asthma were 
at increased risk for IPI and this new risk factor accounted for 5% of the overall 
disease burden. One tenth of pneumococcal bacteremias were healthcare-as-
sociated, and mortality among these patients was over twice as high as among 
patients with community-associated bacteremia. Most patients with nosocomial 
infections had underlying conditions for which PPV23 is recommended. The study 
findings underscore the urgent need for improved prevention efforts for pneumo-
coccal infections through use of pneumococcal vaccines.
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ABSTRACT 
Background and aims. Streptococcus pneumoniae is a leading cause of pneumonia, 
meningitis and bacteremia worldwide. The 23-valent pneumococcal polysaccharide 
vaccine (PPV23) is recommended for adults under 65 years with certain chronic medical 
conditions and for all elderly persons because of high rates of invasive pneumococcal 
infections (IPI) and increased risk of death. Representative, population-based 
information about the risk factors and clinical outcome of IPI is limited. National data to 
determine the disease burden and new risk groups are important for planning vaccination 
programs. Information about increased risk of IPI among patients with asthma is limited 
and the characteristics, risk factors, and outcome of infection in patients with nosocomial 
pneumococcal bacteremia (NPB) seldom appear in large, population-based studies. The 
objective of this study was to provide baseline data on the epidemiology of IPI in 
Finland before the introduction of childhood pneumococcal conjugate vaccines with 
special emphasis on the incidence, risk factors for IPI, outcome, the role of asthma, and 
healthcare-associated IPI. 
Methods. This study was based on national, population-based laboratory surveillance for 
IPI. Information on all episodes of IPI was collected from the primary diagnostic 
laboratory. A case with IPI was defined as the isolation of S. pneumoniae from blood or 
cerebrospinal fluid (CSF) or both during 1995-2002. Pneumococcal bacteremia was 
defined as nosocomial if the first positive blood culture was obtained more than two 
days after hospital admission or if the patient had been hospitalized for more than two 
days within seven days of the first positive blood culture. Information about the annual 
numbers of blood culture and CSF sets processed during the study period were obtained 
through a survey of all clinical microbiology laboratories. Information on comorbidities 
and underlying conditions for IPI patients was obtained by linking the IPI surveillance 
database to other national, population-based health registries using each patient’s unique 
national identity code. For each IPI case with chronic lung disease aged 18-49 years, ten 
age, gender-, and health district-matched controls were selected from the Population 
Information System.  
Results: In total, 4357 cases of IPI were identified: 94.2% were bacteremias and 5.7% were 
meningitis. Of the cases, 58.2% were males, and the median age was 52.6 years. The 
  
overall annualized IPI incidence was 10.6 per 100 000 population. The rate in children 
under five years was 23.5 per 100 000. Regional pneumococcal bacteremia rates were 
correlated with blood culture sampling rates (P= 0.015), but meningitis rates did not 
correlate with CSF culture rates. During the study period, the overall annual IPI rate 
increased by 35.1%, and the annual blood culturing rate increased by 29.6%. 
Pneumococcal serotypes included in the 7-valent conjugate vaccines caused 69.8% of IPIs 
among children under five years and 49.5% in adults, respectively. Of the 4357 cases with 
IPI, those aged 18-49 and 50-64 years accounted for 29.4% and 21.4% of IPI cases, of 
which 29.0% and 45.7% showed a current indication for PPV23, respectively. Overall, 
12.3% of IPI patients died within one month of the first positive culture. Persons aged 18-
64 years accounted for 47.4% of all deaths (case-fatality proportion, 11.5%). Of those who 
died, 46.0%  showed no vaccine indication.  Overall, 7.4% of cases had a chronic lung 
disease. After adjustment for other independent risk factors in a conditional logistic 
regression model, IPI was associated with both low-risk asthma (LRA) (matched  OR, 
2.8; 95 % CI, 2.1-3.6) and high-risk asthma (HRA) (matched OR, 12.3; 95% CI,  5.4-
28.0). The adjusted population-attributable risks for HRA and LRA were 0.010 (95% CI, 
0.0035-0.017) and 0.039 (95% CI, 0.023-0.055), respectively. Of the 3973 pneumococcal 
bacteremias, 9.7% had NPB. Patients with NPB were significantly older (P<0.001) and 
were more likely to have at least one high-risk condition (other than age 65 years or older) 
for which PPV23 is recommended, than were patients with community-associated 
pneumococcal bacteremias (CAPB). The case-fatality at 28 days was higher in patients 
with NPB than in CAPBs (23.8% vs. 10.8%,  P< 0.001). 
Conclusions: The true incidence of IPI in Finland may be higher than previously 
estimated. In the general population of non-elderly adults, two-thirds of invasive 
infections and one half of fatal cases occur in persons with no recognized PPV23 
indication. Asthma is associated with a moderately higher risk of IPI, to which 
approximately 5% of the disease burden can be attributed. About 10% of all 
pneumococcal bacteremias were healthcare-associated, and mortality among patients 
with NPB was over twice as high as among patients with CAPB. Most of the patients 
with nosocomial disease exhibited underlying conditions for which PPV23 is 
recommended. The findings of this study emphasize the need for improved prevention 
efforts against pneumococcal infections through increased use of PPV23 in adult risk 
groups and introduction of childhood immunization with pneumococcal conjugate 
vaccine in Finland. 
Keywords: asthma, bacteremia, epidemiology, invasive pneumococcal infections, 
meningitis, nosocomial pneumococcal bacteremia, outcome, public health, risk factors, 
pneumococcal vaccines 
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TIIVISTELMÄ 
Tausta ja tavoitteet. Streptococcus pneumoniae on maailmanlaajuisesti yleinen 
keuhkokuumeen, aivokalvotulehduksen ja bakteremian aiheuttaja. Pneumokokki-
polysakkaridirokotetta (PPV23) suositellaan kaikille vanhuksille ja alle 65-vuotiaille 
aikuisille, joilla on perussairautensa vuoksi erityisen suuri riski sairastua ja kuolla 
invasiiviseen pneumokokki-infektioon (IPI). Edustavaa väestötason tietoa IPI:n 
riskitekijöistä ja kuolleisuudesta on vähän. Tietoa kansallisen tason tautitaakasta ja 
uusista riskiryhmistä tarvitaan rokotusohjelmien suunnittelussa. Myös tieto 
astmapotilaiden riskistä sairastua IPI:in on ristiriitaista ja sairaalasyntyisen pneumo-
kokkibakteremian erityispiirteitä, riskitekijöitä ja kuolleisuutta ei ole aiemmin 
selvitetty laajoissa väestöpohjaisissa tutkimuksissa. Tämän tutkimuksen tavoitteena oli 
kerätä perustietoa IPI:n epidemiologiasta Suomessa ennen lapsille suunnatun 
pneumokokkikonjugaattirokotteen käyttöönottoa. Kiinnostuksen kohteena oli 
erityisesti IPI:n ilmaantuvuus, riskitekijät ja kuolleisuus sekä astman ja sairaala-
syntyisen IPI:n merkitys. 
Menetelmät. Tutkimusaineisto perustui kansalliseen, väestöpohjaiseen IPI:n 
laboratorioseurantaan. IPI-tapaukset kerättiin kliinisen mikrobiologian laboratorioista. 
IPI-tapauksen määritelmä oli veren ja/tai likvorin positiivinen S. pneumoniae -
viljelylöydös vuosina 1995–2002. Pneumokokkibakteremia luokiteltiin sairaala-
syntyiseksi, jos pneumokokki oli viljelty toisen sairaalahoitopäivän jälkeen otetusta 
näytteestä tai jos potilas oli ollut sairaalahoidossa kauemmin kuin kaksi päivää 
edeltävän viikon kuluessa ensimmäisen positiivisen veriviljelynäytteen jälkeen. 
Kyselytutkimuksella kerättiin tiedot vuosittaisista veri- ja likvorviljelymääristä 
kliinisen mikrobiologian laboratorioista. Tiedot potilaan perussairauksista saatiin 
yhdistämällä IPI-tutkimusaineisto kansallisiin väestöpohjaisiin terveydenhoito-
rekistereihin henkilötunnuksen avulla. Jokaiselle 18–49-vuotiaalle kroonista keuhko-
sairautta sairastavalle IPI-tapaukselle valittiin 10 iän, sukupuolen ja asuinpaikan 
suhteen vakioitua kontrollia väestötietojärjestelmästä. 
Tulokset: Kaikkiaan todettiin 4357 IPI-tapausta, joista 94,2 % oli bakteremioita ja 5,7 % 
aivokalvontulehduksia. Tapauksista 58,2 % oli miehiä ja heidän iän mediaani oli 52,6 
vuotta. IPI:n keskimääräinen vuosittainen ilmaantuvuus oli 10,6/100 000 
  
henkilövuotta. Alle 5-vuotiailla lapsilla ilmaantuvuus oli 23,5/100 000. Alueelliset 
pneumokokkibakteremiaesiintyvyydet korreloivat veriviljelyottoaktiviteetin kanssa 
(P=0.015), kun taas aivokalvotulehduksen ja likvorviljelyjen välillä ei vastaavaa 
yhteyttä todettu. Tutkimusjakson aikana vuosittainen IPI-ilmaantuvuus lisääntyi 35,1 % 
ja vuosittaiset veriviljelymäärät 29,6 %. Alle 5-vuotiailla 7-valenttiseen konjugaatti-
rokotteeseen kuuluvat serotyypit aiheuttivat 69,8 % IPI-tapauksista ja aikuisilla 
vastaavasti 49,5 %. Kaikista IPI-tapauksista 29,4 % esiintyi 18–49-vuotiailla ja 21,4 % 
50–64-vuotiailla: 18–49-vuotiaista 29,0 %:lla ja 50–64-vuotiaista 45,7 %:lla oli 
PPV23-rokoteindikaatio. IPI-tapauksista 12,3 % kuoli kuukauden kuluessa 
ensimmäisen positiivisen viljelynäytten jälkeen. Kuolleista 47,4 % kuului ikäryhmään 
18–64 (tappavuus, 11,5 %). Menehtyneistä 46,0 %:lla ei ollut PPV23-rokote-
indikaatiota. Kaikista tapauksista 7,4 %:lla oli krooninen keuhkosairaus. Kun muut 
itsenäiset riskitekijät oli huomioitu logistisessa regressiomallissa riski sairastua IPI:in 
liittyi sekä matalan riskin astmaan (kaltaistettu vetosuhde, 2,8; 95 % luottamusväli, 
2,1-3,6) että korkean riskin astmaan (kaltaistettu vetosuhde, 12,3; 95 % luottamusväli, 
5,4-28,0). Korkean riskin astman ylimääräosuus väestössä oli 0,010 (95 % 
luottamusväli, 0,0035-0,017) ja matalan riskin astman 0,039 (95 % luottamusväli, 
0,023-0,055). Sairaalasyntyinen pneumokokkibakteremia todettiin 9,7 %:lla pneumo-
kokkibakteremiatapauksista (n=3973): verrattuna avohoidon tapauksiin sairaala-
syntyiset olivat merkitsevästi iäkkäämpiä ja heillä oli vähintään yksi riskitekijä (muu 
kuin ikä ≥65 vuotta), johon PPV23-rokotetta suositellaan annettavaksi. Tappavuus 28 
päivän sisällä oli sairaalasyntyisillä pneumokokkibakteremiatapauksilla merkitsevästi 
korkeampi kuin avohoidon tapauksilla (23,8 % vs. 10,8 %, P< 0.001). 
Yhteenveto: IPI:n ilmaantuvuus on todennäköisesti aiempia arvioita korkeampi. 
Työikäisten keskuudessa kaksikolmasosaa infektioista ja puolet kuolemista esiintyy 
henkilöillä, joilla ei ole PPV23-rokoteindikaatiota. Astmaan liittyy kohtalaisen suuri 
riski sairastua IPI:in ja se kattaa noin 5 % IPI:n kokonaistautitaakasta. Noin 10 % 
kaikista pneumokokkibakteremiatapauksista oli sairaalasyntyisiä ja niihin liittyvä 
kuolleisuus oli suurempi kuin muualla saatuun liittyvä. Suurimmalla osalla 
sairaalasyntyisistä tapauksista oli joku PPV23-rokoteindikaation mukainen perus-
sairaus. Tämän tutkimuksen tulokset korostavat pneumokokki-infektioiden 
ennaltaehkäisyn tehostamisen tärkeyttä Suomessa pneumokokkirokottein. 
Asiasanat: aivokalvotulehdus, astma, bakteremia, epidemiologia, invasiiviset pneumo-
kokki-infektiot, kuolleisuus, pneumokokkirokotteet, riskitekijät, sairaalasyntyinen 
pneumokokkibakteremia 
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1 INTRODUCTION 
Streptococcus pneumoniae (pneumococcus) is a leading cause of pneumonia, 
meningitis, and bacteremia worldwide and affects mainly young children, the elderly, 
and persons with certain underlying medical conditions. Pneumococcal infections are 
estimated to be responsible for 1-2 million deaths in children every year and likely for 
a similar number among adults (1). For more than 120 years, the study of 
Streptococcus pneumoniae and pneumococcal infections has played a central role in 
the development of a scientific basis for the control of infectious diseases (2-4). 
Infections of the middle ear, tracheobronchial tree, and lung stem from the direct 
spread of the bacteria from the nasopharynx. Pneumococcus may also cause systemic 
infections and invasive pneumococcal infection (IPI) in which S. pneumoniae is 
isolated from the bloodstream or other normally sterile sites such as cerebrospinal 
fluid (CSF), synnovial or pleural fluids (5). 
The reported incidence and serotype distribution for IPI varies globally and over 
time. Differences in observed rates of IPI between countries and jurisdictions may 
stem from differences in diagnostic activity and surveillance systems, population 
demographics, and the prevalence of risk factors for IPI (6, 7). Few studies (8, 9) 
have evaluated the relationship between the incidence of IPI and blood culturing 
rates in different catchment areas and over time, and to my knowledge, none have 
assessed the relationship between IPI and CSF culturing rates.                                                                
The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for 
all adults aged 65 years and older as well as for younger adults with certain chronic 
medical conditions because of their high disease rates and increased risk of death 
(10-12). Estimates of the effectiveness of PPV23 against IPI, although somewhat 
inconsistent, are generally highest among otherwise healthy young adults (13-16), 
but lower among persons with multiple underlying medical conditions and 
immunosuppression (17, 18). Available information from representative, population-
based studies on the outcome of IPI is limited. Case fatality has generally been 
defined as in-hospital mortality without extended follow-up after discharge from the 
hospital (10, 11). 
Chronic obstructive pulmonary diseases (COPD) is an established risk factor for IPI 
(19), but asthma is not universally accepted as an indication for PPV23 (20), and 
available information about the higher risk of IPI among persons with asthma is limited. 
Streptococcus pneumoniae predominantly causes community-acquired respiratory 
tract, central nervous system, and bloodstream infections, but its role in healthcare-
  17
associated infections remains poorly defined (21, 22). Institutional outbreaks of IPI 
and multidrug-resistant S. pneumoniae have been reported, and the prevalence of 
antimicrobial resistant strains may be higher in older adults living in long-term care 
facilities (23-27). Among such adults, IPI is an important cause of illness and death, 
thus underscoring the need for better prevention efforts through immunization (28).  
The purpose of this study was to provide comprehensive baseline information on the 
epidemiology of IPI in Finland before the introduction of routine childhood 
immunization with pneumococcal conjugate vaccine. Linking population-based 
surveillance data collected during the eight-year study period with data available in 
national healthcare registries enabled us to define the pneumococcal disease burden 
as well as the incidence, established and new risk factors, clinical outcome, and the 
contribution of healthcare-associated pneumococcal infections. This study also 
points to the multiple opportunities for preventing pneumococcal infections in 
Finland where the use of pneumococcal vaccines has thus far been minimal.  
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2 REVIEW OF THE LITERATURE 
2.1.1  Background (Streptococcus pneumoniae) 
In the 1880s, Streptococcus pneumoniae was recognized as the major cause of 
pneumonia. During the 20th century, the bacterium has played a central role in the 
history of microbiology and humoral immunology, as well as in the discovery of 
DNA (29-31). The organism was almost simultaneously isolated and grown in 
laboratories in the USA and France by Sternberg and Pasteur, respectively, in 1880. 
The late 1880s saw the introduction of the term pneumococcus and the official name 
Diplococcus pneumoniae. In 1974, the organism was reclassified as Streptococcus 
pneumoniae on the basis of its growth in chains in liquid media (32).  
S. pneumoniae is a gram-positive coccus that grows in chains and is catalase-
negative. It produces pneumolycin, a toxin that breaks down hemoglobin, thus 
causing alpha-hemolysis on blood agar. Further, the bacterium is characterized by its 
susceptibility to optochin and solubility in bile salts. 
Almost all clinical isolates of S. pneumoniae contain an external polysaccharide 
capsule. To date, 91 distinct capsules are known. Types that are antigenically related 
to each other are included in groups (e.g. 19F, 19A, 19B, and 19C), whereas types 
with no close relationship to other types are designated with numbers only (33). The 
polysaccharide capsule is of great importance for virulence (34). 
Pneumococcus is a commensal member of the oral streptococci and is primarily 
carried asymptomatically (35-37). The bacterium colonizes the nasopharynx and can 
be isolated from 5% to 10% of healthy adults and from 20% to 40% of healthy 
children. The rate of colonization seems to be seasonal, peaking in mid-winter (38). 
On the other hand, a better-known characteristic of this organism is its association 
with widespread morbidity and mortality. Infection usually takes place as a result of 
the spread of the bacteria to cavities from which they are not readily cleared (e.g. 
sinuses, Eustachian tubes, and bronchi). Viral infection, environmental factors, such 
as cigarette smoke or other toxic substances, and allergies may impair the clearance 
of the organism, and thus promote infection. Pneumococci may also directly interact 
with surface receptors on epithelial and mucosal cells and enter the blood stream 
(39), thus causing invasive infection. IPI is defined as an infection in which S. 
pneumoniae is isolated from blood, CSF, or other normally sterile sites (e.g. pleural, 
peritoneal, and synnovial fluids). 
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2.1.2   Public health impact 
S. pneumoniae is a leading cause of infection-related morbidity and mortality. The 
organism is endemic worldwide and causes a wide range of diseases ranging from 
non-severe upper-respiratory infections to severe, life-threatening invasive 
infections.  
The World Health Organization (WHO) has estimated that 1.6 million people die 
annually from pneumococcal disease, an estimate that includes the death of 0.7-1 
million children under five years  (40). The disease burden is remarkable. In the 
USA, S. pneumoniae is the most common cause of otitis media, accounting for more 
than 16 million medical visits annually. Prior to the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) in the USA, pneumococcus was 
responsible for 500 000 cases of pneumonia, 60 000 cases of bacteremia, 3 000 
cases of meningitis, and 200 childhood deaths annually (41). The FinOM study (42) 
reports that 40 000 episodes of pneumococcal otitis media occur annually in Finland 
among children under two years. A study by Heiskanen-Kosma (43) identifies the 
incidence of pneumococcal pneumonia in children under five years  as 8.6 cases per 
1 000, which translates to approximately 2 500 cases of pneumonia annually. 
Among the elderly, the burden of pneumococcal pneumonia is even greater, with an 
incidence of 14.8 per 1 000 in those aged 60 years or older (44). A review by 
Mulholland estimated that 70% of severe pneumonia is of pneumococcal origin (45). 
In some countries, empyema and pulmonary abscesses have become more common 
as a complication of particularly pneumococcal pneumonia since the 1990s (46-49). 
In a report from a pediatric tertiary care clinic in Finland, the prevalence of 
empyema among cases of uncomplicated pneumonia increased from 0.5% to 3.3% 
during 1991-2006. S. pneumoniae was verified from pleural fluid in 46% of the 
empyema cases (50). 
Of all documented IPI among adults, more than 90% are bacteremias and 5% to 
10% are meningitis (51). Of all bacteremic infections in Finland during 1995-2004, 
S. pneumoniae was the fourth most common isolate among those aged 15-64 years 
and the sixth most common among those aged 65 years or older, thus accounting for 
10% to 12% and 5% to 7% of cases, respectively (52). In England and Wales, 
pneumococcus is the third most common isolate reported from blood cultures of 
patients of all ages and the most common in children in the USA (53). Other clinical 
manifestations of IPI, such as peritonitis, septic arthritis, and purulent pericarditis, 
are rare, constituting 2% to 5% of cases (54-58). In children, the clinical 
presentation of IPI has been bacteremia with no focus in 57% to 71% of cases, 
pneumonia in 10% to 15% of cases, and meningitis in 8% to 14% of cases (59-62). 
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Antibiotic resistance is an increasing public health problem in many countries. In 
Europe, the resistance pattern has a dynamic character. During 1999-2007, penicillin 
non-susceptibility of S. pneumoniae (PNSP) is increasing in Turkey and Finland; on 
the other hand, it is decreasing in some countries, among those three countries 
showing the highest PNSP rates in 2006 (63). Erythromycin non-susceptibility is 
becoming more prevalent in several countries. In Finland this increase is very 
pronounced (6% in 1999 vs. 26% in 2007), and severe cases of IPI and pneumonia 
have been detected due to failure of initial macrolide treatment (63-65). 
2.1.3    Surveillance 
The surveillance system of IPI greatly impacts the reported incidence rates and 
mortality of the disease. Surveillance systems differ considerably between countries, 
and particularly between developing and developed ones. This fact makes country-
based and even regional comparison complicated. The kind of information the 
surveillance is based on is fundamental to interpreting the results. Issues of 
importance are whether the surveillance is active or passive, nationwide, regional or 
sentinel-based, statutory or voluntary. Further, whether the system relies on 
laboratory-based data, clinical surveillance, or a combination of both, and whether 
cases are defined with non-culture or culture methods or both, is crucial.  
In the USA, the Active Bacterial Core surveillance (ABCs) at the Centers for 
Disease Control and Prevention (CDC) provides comparable national data on the 
incidence of IPI in ten Emerging Infections Program Network sites, representing a 
population of over 28 million (66). Surveillance for IPI in Europe is very 
heterogeneous, and several countries lack surveillance systems altogether (67). 
Large differences in reported disease incidence may reflect both true differences as 
well as variations in patient and healthcare factors, including surveillance. A number 
of European countries lack serotype information, which is critical to ascertaining the 
coverage of PCV7 and other pneumococcal vaccines. Although a large number of 
IPI episodes are reported through surveillance in Europe, reported IPI rates vary 
greatly between countries (67-69). 
An important difference between IPI rates reported in the USA and those reported 
by European surveillance systems stems from blood culture practice. In Europe, 
most positive pneumococcal blood cultures have been taken from hospitalized 
patients with a more severe disease, whereas in the USA, a significant proportion 
(79% among children under two years ) of IPI isolates comes from outpatients with 
a milder disease  (53, 68, 70).  
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2.1.4   Incidence 
Data from population-based studies carried out in different parts of the world show 
that the overall rate of IPI is about 15 per 100 000 persons (38). Estimates suggest 
that a more correct figure in North America and Europe may be more than 40 per 
100 000 (33, 71, 72). The age-distribution of IPI is typically bimodal with the 
highest peaks in newborns and infants up to two years and in adults over 65 years. 
The shape of the incidence curve remains unchanged compared to that of the 
preantibiotic era, although the overall incidence of IPI in the population has declined 
markedly (38). Few studies have reported incidence rates among non-elderly adults 
aged 18-64 years even though this age group contributes to the largest absolute 
number of cases (73-76) (Table 1). Before the introduction of PCV7 in the USA, the 
annual incidence among children 6-11 months was 235, and 166.9 per 100 000 in 
children under two years, respectively (10, 77); in the U.K., the incidence is 21.1-
36.2 per 100 000 children under one year (78). Among the elderly (over 65 years ) in 
developed countries, the incidence of IPI has been estimated at 50 per 100 000 
persons (69). For the same age-group during the pre-conjugate vaccine era, higher 
rates were reported from the USA (19, 74, 79-82) and lower rates from Europe (78). 
Particularly among children, geographical variations in incidence can be attributed 
to variations in blood culture practices as described in section 2.1.3. Studies have 
also shown that variation in blood culture sampling rates can explain differences in 
IPI or S. pneumoniae bacteremia (SPB) rates within geographical regions, as 
illustrated in Southwestern England and Finland (8, 9, 83). Because a vast majority 
of adult patients with IPI also have bacteremic pneumococcal pneumonia, variation 
in the frequency with which blood cultures are obtained in pneumonia patients may 
explain many of these differences (74, 84, 85). 
Rising trends in bacteremia and mostly stable S. pneumoniae (SPM) rates have been 
reported in Sweden, Norway, Scotland, UK, South Carolina, USA and Denmark 
during 1989-1994, (79, 86-89). In contrast, declining observed rates of 
pneumococcal bacteremia were reported in Denmark during 1995-1999 (90), but 
rising rates of IPI were again reported during 2000-2005, due mainly to a rise in 
bacteremia rates (91). Following large-scale immunization against Hemophilus 
influenzae type b in children, S. pneumoniae has become the most common cause of 
bacterial meningitis. The incidence of SPM in the developed world has remained 
stable at around 0.5-1.0 per 100 000 (92, 93). 
The incidence also varies according to ethnicity and race. In the pre-conjugate 
vaccine era in the USA, black adults had a three-fold to five-fold higher overall rate 
of SPB than did whites (74, 75, 79, 94, 95). Studies have shown that Australian 
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Aborigines (96) and many Native American populations have a higher incidence of 
IPI in children under two years  (97-99). 
2.1.5   Mortality 
Before the era of serum therapy and antibiotic treatment, mortality due to IPI was 
higher than 80% (100). Following the introduction of penicillin, the case-fatality rate 
dropped radically, but despite appropriate treatment and modern intensive care, has 
remained between 7% and 36% during the past few decades (101). Among young 
children, CFPs are generally less than 2% in developed countries. In the USA, IPI 
accounts for more deaths than any other vaccine-preventable bacterial infection 
(102, 103). Almost half of these deaths occurred in persons aged 65 years or older, 
and 48.1% in persons aged 18-64 years (66). Pneumonia is the most common cause 
of IPI-related mortality, and the elderly are more likely to have pneumonia rather 
than primary bacteremia. This may, at least partly, explain why IPI-related mortality 
among elderly increases with age (104).   
In publications from the last ten years, overall IPI-related mortality has ranged 
between 6% and 27.8% (Table 1). The CFP varies considerably depending on age-
group, underlying medical conditions, type of infection (SPB vs. SPM) and the time-
point at which CFP is defined. The highest case fatality have occurred among 
persons of advanced age and with underlying diseases (104), particularly cirrhosis 
and alcohol abuse (11). Case fatality also varies significantly by geographic region 
(104) (Table 1). These differences most likely reflect variations in underlying 
conditions, hospitalization, and blood culturing practices (104, 105). Among non-
elderly adults, the CFP is 2.2 times higher when the IPI case has an underlying 
condition for which PPV23 is recommended (10). The CFP of SPM varies between 
15% and 25% (Table 1).  
 
  
2.1.6   Invasive pneumococcal disease in Finland 
In Finland, three previous nationwide studies have been conducted on the incidence 
of IPI, of which only one included all age-groups, and the remaining two, children 
(Table 2). In the late 1970s, the incidence of SPB and SPM was 2.7 and 0.6 per 
100 000, respectively, among persons of all ages (122). In this study, S. pneumoniae 
was the fourth (7.8%) most common cause of bacteremia, and 36% of SPB cases 
occurred among children between one month and four years. Among Finnish adults 
from three different geographical areas (Southern, Central and Northern Finland), 
the overall annual incidence of IPI was 9.1 per 100 000, but the incidence rose from 
27.1 through 35.8 to 44.5 per 100 000 among those aged 65 years or older, 75 years 
or older, and 85 years or older, respectively (85). The incidence of SPB and SPM 
was 8.2 and 0.9 per 100 000.  
The incidence of IPI in a nationwide laboratory-based surveillance among Finnish 
children was 8.9, 24.2, and 45.3 per 100 000 among those under 16 years, under five 
years, and under two years, respectively (59). In the catchment area of the Tampere 
University Hospital, the incidence of bacteremic pneumococcal infections among 
children under 16 years  was 10.5 per 100 000, and among those under two years, 53 
per 100 000 during the ten-year period 1983-1992 (123). In a nationwide and 
population-based case-control study among children under 16 years, daycare center 
or family daycare attendance and a history of frequent otitis media associated with a 
higher risk for IPI among children under two years  (124).  
Three Finnish studies report the outcome of IPI. Among children under 15 years, the 
CFP was about 1% (59). Researchers studied pneumococcal bacteremia among adult 
patients admitted to the Helsinki University Central Hospital during two periods 
(55). The overall CFP was 21%, and the rate showed a small decrease from 28% in 
the 1970s to 17% in the late 1980s. The most common underlying factors were 
alcohol abuse, cardiovascular diseases, and COPD. In a study from the Turku 
University Central Hospital, the CFP was 34% among adult patients with SPB (56). 
Of those patients, 70% had at least one chronic underlying disease and 31% were 
classified as alcohol abusers. 
Jokinen (125) studied the incidence and etiology of pneumonia in Eastern Finland. 
The overall incidence of pneumonia was 13 per 1000, and in 19% of 
microbiologically verified cases, the causative agent was S. pneumoniae. Among 
persons aged 60 years or older in a municipality in Eastern Finland, pneumococcal 
pneumonia was serologically diagnosed in 40% of all pneumonia episodes, thus 
corresponding to an incidence of 7.0 per 1000 person-years (126). The overall 
27
  
pneumonia-related mortality rate among the elderly was 8.7 per 1000 person-years. 
If the initial pneumonia episode was pneumococcal, the subsequent mortality was 
three times higher than among other elderly inhabitants of the same area. In a study 
among children under 15 years in four municipalities in Eastern Finland, 28% of 
pneumonias were caused by S .pneumoniae (43).  
28
  
2.2  Factors influencing the risk of invasive pneumococcal 
infections 
2.2.1 Host factors 
Being under 2 or 65 years or older is a well recognized risk factor for IPI. Compared 
to adolescent, the incidence can be as much as 50 times higher (99). The increased 
risk of disease among children under two years  seems to be related to an immature 
immunologic response to the polysaccharide capsule and to the high prevalence of 
colonization (128). Among the elderly, higher rates of underlying medical 
conditions and age-related immune dysfunction contribute to the increased risk for 
IPI (129). On the other hand, Sims et al. (130) have shown that age is also 
independently associated with the risk for pneumococcal infections even when 
controlling for other risk factors. Several studies overrepresented the rates of IPI 
among males (10, 74, 75, 79, 131), and in a case-control study with 
immunocompetent non-eldererly adults, male gender was an independent risk factor 
for invasive infection (76). Underlying conditions such as smoking and alcoholism 
are more common among males, which may also explain the predominance of males 
(33). 
Many underlying medical conditions are believed to increase the risk for and 
severity of IPI. Even if the strength of the evidence documenting the risk associated 
with each condition varies, these conditions are considered indications for PPV23 in 
many countries, including Finland (Appendix 1). In population-based studies, the 
rate of IPI among patients with various immunocompromising conditions varies 
from 33 to 547 per 100 000, and is highest among those with hematological 
malignancy. In immunocompetent patients (persons with diabetes mellitus, chronic 
pulmonary disease, and cardiac failure) rates vary less (range, 12-47 per 100 000). 
These studies reported higher rates for solid cancer (216 to 300 per 100 000), 
chronic pulmonary disease (63 to 503 per 100 000) and HIV (423 to 2031 per 100 000)
(11, 75, 132). 
Different pathophysiological mechanisms may explain increased susceptibility to S. 
pneumoniae and severe disease manifestations among persons with underlying 
disorders. Children and adults with functional and anatomic asplenia are at markedly 
increased risk for bacteremia, which is also associated with high fatality (133-137). 
Splenic dysfunction leads to the impaired clearance of encapsulated bacteria from 
the bloodstream (138), and persons with sickle-cell anemia are at particularly high 
risk (139). Congestive heart failure, but not ischemic heart disease, is associated 
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with both all-cause pneumonia and IPI. The precise mechanism remains unknown, 
however (140, 141). Diabetes mellitus is associated with decreased immunity, risk 
for metabolic derangement, and angiopathy followed by cardiovascular and renal 
dysfunction (142-145). In two recent population-based studies in Denmark, the risk 
for pneumococcal bacteremia was higher among young adults and patients with no 
other coexisting comorbidity. Diabetic patients appeared to have no higher case 
fatality than did nondiabetic patients (109, 146). The risk of IPI is especially high in 
persons with chronic lung diseases, such as COPD and emphysema, probably due to 
poor ciliary function (75). The effect of alcoholism is multifactorial and includes 
lifestyle-related issues such as cold exposure, malnutrition, and cigarette smoking, 
as well as suppression of the gag reflex and the impaired function of neutrofils (147-
152). Some population-based studies list about one third of patients with IPI as 
alcoholics (142, 143, 153). Both alcohol- and non-alcohol-related liver disease is 
related to a higher risk for severe pneumococcal infections; persons with cirrhosis 
suffer a particularly high fatality rate (75, 153, 154). 
 
S. pneumoniae is the most common pathogen to infect persons with hematological 
malignancies (multiple myeloma, leukemia and lymphoma) before chemotherapy 
and hospitalization tip the balance toward gram-negative infections (38, 155). 
Pneumococcus is the leading cause of community-acquired pneumonia and 
bacteremia in patients with HIV infection and increases the risk for IPI as much as 
10- to 100-fold over that of the general population (7, 156-158). Some researchers 
have even suggested that bacteremic pneumococcal pneumonia and unusual 
pneumococcal infections in young adults should trigger a search for HIV infection 
(159, 160). After the introduction of highly active antiretroviral therapy (HAART) 
in the mid-1990s, the incidence of IPI dropped by 50% among persons living with 
AIDS (161). Mortality among HIV patients with IPI seems to be no higher than 
among non-HIV infected patients, which may stem from the fact that a majority of 
the patients are young, with no other underlying conditions, and are monitored 
closely by medical care (33). In a multicenter study, however, mortality at 14 days 
was significantly higher among those with lower CD4 counts (162).  
2.2.2   Socioeconomic factors and living conditions 
Pneumococcal infection disproportionately affects persons of lower socioeconomic 
status (75, 79). Studies in the USA suggest the association may be confounded by 
over-representation of blacks among low-income IPI cases. A study in metropolitan 
Atlanta, however, showed that the difference in rates of invasive disease between 
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blacks and whites decreased in areas with higher incomes, and rates were nearly the 
same at the highest income levels (163). In a case-control study by Nuorti et al. (76), 
low household income was not significantly associated with the risk for illness, but a 
low level of education proved to be a strong independent risk factor after controlling 
for confounding factors.  
Overcrowding is also a risk factor for sporadic IPI and outbreaks of invasive disease in 
both institutional and non-institutional settings. Studies from different countries show 
that daycare attendance is strongly associated with increased risk for IPI (124, 164-166). 
Within-family colonization, particularly after the age of six months, may cause clusters 
of illnesses stemming from the same serotype of S. pneumoniae (36, 167). 
2.3  Chronic pulmonary diseases and invasive pneumococcal 
infections 
Chronic obstructive pulmonary diseases are established risk factors for invasive 
pneumococcal infections (19), but asthma without systemic corticosteroid use is 
currently not considered an indication of PPV23 in Finland and many other 
countries (20, 168) (Appendix 1). Asthma prevalence continues to rise globally 
(169, 170). An estimated 4.4% of Finnish adults have asthma and the prevalence 
has risen since the 1960s (171, 172). Available information regarding whether 
asthma is associated with increased risk for IPI is limited and somewhat inconsistent 
(173, 174). A recent study of persons aged 2-49 years enrolled in the Medicaid 
program in one US state, where cases of IPI were identified thorough active 
population-based surveillance, suggested that asthma moderately increased one’s 
risk for IPI (OR 2.4, 95% CI 1.9-3.1) (173) (Table 3). However, another recent study 
of mostly older adults (average age over 50 years) used administrative data from the 
U.S. Veteran’s Administration Healthcare system and found that persons with 
COPD were at greater risk for hospitalization for pneumococcal pneumonia than 
were control subjects, but persons with asthma were not (174). A retrospective study 
(1964-1983) in Rochester, NY (USA), which included both IPI and pneumococcal 
pneumonia and controlled for high-risk conditions for IPI and smoking exposure, 
showed that serious pneumococcal disease was associated with a history of asthma 
among all ages (OR 2.4, 95% CI 0.9-6.6) and among adults (OR 6.7, 95% CI 1.6-
27.3) (175). The population-attributable risk (PAR) in adults of this study was 17%, 
and in a study by Talbot et al., was calculated to be 11% in adults (173). The PAR 
for all combined vaccine-eligible (Advisory Committee on Immunization Practices 
(176)) conditions in adults was 24%, suggesting that at a population level, asthma 
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status alone disproportionately increases the burden of serious pneumococcal 
disease (175). A study in Scotland reported a case-fatality rate of 3.3% among IPI 
patients with asthma (11). 
A group of persons with asthma can be heterogeneous depending on factors such as 
the intensity and type of medication (immunosuppression) and the need for 
hospitalization. In one study, Talbot et al. (173) defined asthma as either high or low 
risk. High-risk patients were those who required at least one of the following: 1) 
admission to hospital or emergency department, 2) the use of intensive therapy for 
acute asthma attacks, or 3) long-term corticosteroid use or the dispensing of three or 
more prescriptions for β-agonists within the year prior to enrollment in the study. The 
annual incidence of IPI was nearly two-fold higher (4.2 vs. 2.3 per 10 000 persons) 
among patients with high-risk asthma than among those with low-risk asthma.  
With asthma, several pathological alterations in the airways could explain the higher 
risk for IPI. The mucociliary clearance of the bronchi is impaired due to the 
abnormal production of sputum and to airway obstruction (177). These 
abnormalities can serve as a focus for viral infections, which could in turn develop 
into invasive bacterial infections (178-181). Long-term immunosuppressive 
treatment of asthma with corticosteroids may be associated with higher risk for 
pneumococcal disease (19). Other studies have also published information 
suggesting differences in innate and acquired immunity between asthmatic and 
nonasthmatic subjects (177, 182-187).  
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2.4 Nosocomial invasive pneumococcal infections 
The role of S. pneumoniae in healthcare-associated infections remains poorly defined 
(21, 22). Institutional outbreaks of multidrug-resistant S. pneumoniae have been 
reported, and the prevalence of antimicrobial-resistant strains may be higher in older 
adults living in long-term care facilities (23-26). Invasive pneumococcal disease is an 
important cause of illness and death in older adults living in long-term care facilities, 
thus emphasizing the need for better prevention efforts through immunization (28). 
The epidemiology of nosocomial pneumococcal bacteremia (NPB) has previously 
been studied primarily in single hospitals, which may not be representative of all 
healthcare facilities serving the population (189-197), and none of these studies was 
population based. In previous studies, the proportion of SPB among nosocomial 
hospitalized patients varies. Recent studies in Europe report lower proportions (10%-
14%) (194-197) of SPB among such patients, unlike studies in the USA, which report 
higher such proportions, as do previous reports from Spain (25%-29%) (190, 192) 
(Table 4). Reasons for these differences may stem from differences in the populations 
under study, small numbers of cases from individual hospitals (189-195), and the case 
definitions used, as well as from admission criteria and the culture sampling policy. 
NPB has previously been associated with severe underlying conditions, including 
neoplasia, COPD, heart failure, and cirrhosis (197). As with community-associated 
pneumococcal bacteremia (CAPB), NPB is detected predominately during the fall and 
winter (193). In addition, NPB presents as pneumonia as frequently as does CAPB. 
However, substantially greater proportions of patients with NPB may have 
extrapulmonary symptoms, such as gastrointestinal complaints.   
NPB is associated with a higher mortality rate than is CAPB (197). This is 
unsurprising, because NPB occurs primarly in critically ill patients with severe 
underlying diseases. Several studies have reported relatively high case-fatality 
proportions, ranging from 38% to 76% (189, 190, 194).  
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2.5 Prevention  
Pneumococcal infections constitute a considerable global disease burden, and the 
need to prevent these infections by means of vaccination is obvious. The year 1911 
saw the first large-scale vaccine trial of a crude whole-cell pneumococcal vaccine 
(5). The first hexavalent type-specific polysaccharide vaccines were marketed in 
1946, but interest in these was low, probably due to the arrival of penicillin. In 1977, 
the first commercially available 14-valent pneumococcal polysaccharide vaccine 
was licensed in the USA and was replaced in 1983 by a reformulated 23-valent 
vaccine. 
The poor immunogenicity of polysaccharide vaccines in children under two years  
led to the development of second generation vaccines in which capsular 
polysaccharides are conjugated to one of several different proteins (199).  
2.5.1 Pneumococcal polysaccharide vaccine 
PPV23 contains 25 μg of each included, purified capsular polysaccharide antigen of S. 
pneumoniae (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 
18C, 19A, 19F, 20, 22F, 23F, and 33F). The 23 capsular types in the vaccine represent 
approximately 90% of all serotypes that cause invasive disease (33, 200-202).  
In the USA and in most European countries, PPV23 is recommended for persons at 
risk for pneumococcal infections due to age, immunosuppression, and defined 
comorbidities (Appendix 1). In Finland, the vaccine coverage among persons at risk 
is  very low: only about 3% (203), compared to 63.4% among those 65 years  or 
older in the USA (204).  
The protective efficacy of PPV23 in adults against IPI seems scientifically 
overwhelming, ranging from 56% to 81% in case-control studies (13-15, 17) and 
40% to 70% in meta-analyses and observational studies (205-209). Two 
randomized, controlled studies among the elderly have indicated a protective 
efficacy of 60-80% (210, 211).  
The protective role of PPV23 against other forms of pneumococcal infections 
than IPI is more controversial. Several studies have failed to demonstrate a 
significant protective effect of PPV23 against non-bacteremic pneumococcal 
pneumonia, all-cause pneumonia, and pneumonia mortality (206, 212, 213). On 
the contrary, a three-year prospective cohort study of all elderly in Stockholm 
showed a strong indication that pneumococcal vaccination was effective not only in 
38
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the prevention of invasive pneumococcal disease, but also of pneumonia overall, 
although to a low degree (214, 215). Other studies have demonstrated the efficacy of 
pneumococcal vaccination in preventing pneumococcal pneumonia and reducing the 
risk of death due to pneumonia (205), as well as in decreasing the patient’s length of 
stay in hospital (216). 
In most immunocompromised patients, with the exeption of patients having had a 
splenectomy, PPV23 seems to have poor efficacy (201). Nevertheless, given the data 
demonstrating the safety, low cost, and efficacy of PPV23, the use of the vaccine in 
the elderly and individuals at high risk for severe pneumococcal infections is 
considered cost effective (217-219). 
2.5.2 Pneumococcal conjugate vaccine 
PCV7 contains the purified capsular polysaccharides 4, 6B, 9V, 14, 18C, 19F, and 
23F of S. pneumoniae. A 10-valent pneumococcal conjugate vaccine (PCV10) also 
includes 1, 5, and 7F, whereas serotypes 3, 6A, and 19A are added to the 13-valent 
vaccine (PCV13). PCV7 was licensed in 2000 in the USA and in 2001 in the E.U. 
Before the introduction of PCV7, serogroups in the vaccine were responsible for 
almost 90% of IPI in young children in the USA and Canada, and for at least 60% in 
all other regions but Asia, where coverage was 43% (220). 
After the introduction of PCV7 in the USA, the rate of IPI was 69% lower among 
those under two years, but the rate among adults did also decline. In addition, the 
vaccine reduced disease caused by drug-resistant strains (221). A study in Atlanta 
showed that the overall incidence of IPI dropped from 30.2 to 13.2 per 
100 000 following the large-scale introduction of PCV7 (222). A recent meta-
analysis demonstrated that PCV7 prevents not only IPI resulting from S. 
pneumoniae vaccine types with more than 90% efficacy, but also radiologically 
verified pneumonia in children under two years (223).  
Although the experience from the continued effectiveness of PCV7 in the USA is 
encouraging, some researchers have expressed concern about the replacement of 
vaccine serotypes with non-vaccine serotypes. In a study conducted by the CDC 
(ABC surveillance), the annual incidence of disease due to nonvaccine serotypes 
increased from an average of 16.3 cases per 100 000 population during prevaccine 
years to 19.9 cases per 100 000 population in 2004 among children under five years, 
and from 27.0 cases per 100 000 population during prevaccine years to 29.8 cases 
per 100 000 population in 2004 among adults 65 years or older. Significant rises in 
the incidence of disease due to serotypes 3, 15, 19A, 22F, and 33F during this period 
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were observed among both children and the elderly (224). Pelton et al. reported that 
serotype 19A has emerged as the most frequent cause of IPI in Massachusetts, and a 
multi-drug resistant sequence type of 19A has become an important cause of 
invasive disease (225).  
New conjugate vaccines are currently in development that will incorporate 
additional serotypes, but this is probably only a short-term solution to the 
replacement phenomenon. A vaccine based one or more antigens common to all 
serotypes would prove a better solution to this problem (226).  
2.5.3 Other strategies 
In a meta-analysis of influenza vaccine among elderly persons, the efficacy of 
preventing all-cause pneumonia was 50% (95% CI, 28%-56%) (227). Among 
persons developing pneumonia or other pulmonary complications during the 
influenza A (H3N2) Hong Kong pandemic, pneumococcus was the most commonly 
identified bacterial pathogen (228, 229). In experimental studies, adults infected 
with influenza A virus appear to have increased susceptibility to colonization of the 
nasopharynx by S. pneumoniae (230, 231). In a study in Stockholm, Christenson et 
al. found influenza vaccination to have a 58% protective efficacy against IPI among 
the elderly, although the number of patients was too small to obtain statistical 
significance (33, 214). 
Cigarette smoking is a risk factor for IPI. In a community-based case-control study 
of immunocompetent persons aged 18-64 years, the population-attributable risk 
(PAR) was 51% for cigarette smoking, 17% for passive smoking, and 14% for 
chronic illness (76). After controlling for gender, race, chronic illnesses, level of 
education, and exposure to children, IPIs were associated with cigarette smoking 
(OR 4.1, 95% CI, 2.4-7.3) and passive smoking (OR 2.5, 95% CI, 1.2-5.1). Dose-
response relations were determined for the current number of cigarettes smoked 
daily, pack-years of smoking, and time since quitting. The risk returned to baseline 
after ten years. Among HIV-infected adults in San Francisco during the pre-HAART 
era, cigarette smoking was nearly twice as common among those with IPI as among 
controls after controlling for CD4 lymphocyte count, race, vaccination history, and 
contact with children (128, 232). In a recent study evaluating nasopharyngeal 
cultures taken before and 12-15 months after cessation of smoking, the high number 
of pathogens (including S. pneumoniae) and low number of interfering organisms 
revert to normal after complete cessation of smoking (233). Nuorti et al. estimated 
that if the prevalence of cigarette smoking in the USA could be reduced from the 
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current 25% to 15%, the incidence of IPI among nonelderly adults would potentially 
decrease by approximately 18% (76). 
As noted previously, heavy alcohol consumption can be frequent among otherwise 
healthy persons with pneumococcal infections (75, 153). Among certain native 
populations in particular,  alcoholism is the predominate risk factor for IPI (152). In 
Finland, a representative sample of the adult population estimates the prevalence of 
hazardous drinking at 5.8%, and that it is more prevalent among men than among 
women (8.5% vs. 3.1%) (234). 
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3 AIMS OF THE STUDY 
The purpose of this study was to provide comprehensive baseline information on the 
epidemiology of invasive pneumococcal infections (IPI) in Finland before the 
introduction of routine childhood immunization with pneumococcal conjugate 
vaccines. Linking population-based national surveillance data collected during the 
eight-year study period (1995-2002) with data available in multiple national 
healthcare registries and other databases enabled us to define the pneumococcal 
disease burden, including the incidence, established and new risk factors (such as 
asthma), clinical outcomes, and the contribution of healthcare-associated 
pneumococcal infections to the overall disease burden. The findings of the study 
highlight the multiple missed opportunities for preventing pneumococcal infections 
in Finland, where the use of pneumococcal vaccines has thus far been suboptimal, as 
well as the need for developing comprehensive prevention strategies to address this 
major public health problem.  
  
The specific objectives were: 
1. To evaluate regional variation and trends in IPI in Finland and to correlate 
regional pneumococcal bacteremia and meningitis rates with blood and 
cerebrospinal fluid (CSF) culture sampling rates in a population-based 
cohort study. To evaluate the serotype distribution and vaccine coverage of 
currently available and new potential pneumococcal vaccines (I). 
2. To assess the risk of IPI and all-cause mortality among persons with and 
without underlying medical conditions that are considered indications of 23-
valent pneumococcal polysaccharide vaccine (PPV23) by linking data on 
IPI to national healthcare registries and vital statistics (II). 
3. To evaluate the association of chronic pulmonary disease, particularly 
asthma, and IPI among persons aged 18-49 years in a population-based 
case-control study (III). 
4. To study the characteristics, risk factors, and outcome of patients with 
nosocomial pneumococcal bacteremia (NPB) in a population-based cohort 
study (IV). 
 
  43
4 MATERIALS AND METHODS 
4.1 Surveillance of invasive pneumococcal infections in Finland 
In Finland (1995-2002: population 5.2 million), the national healthcare system is 
organized into 20 geographically and administratively defined healthcare districts 
(HCD) with catchment populations ranging from 68 000 to 1.4 million. Since 1995, 
all Finnish clinical microbiology laboratories have been required to notify bacterial 
isolations from blood and CSF, including S. pneumoniae, to the National Infectious 
Disease Register (NIDR) at the National Public Health Institute (KTL). Most 
laboratory reporting is currently done electronically. With each notification, the 
following information is transmitted to NIDR: date and type of specimen, date of 
birth, gender, and place of treatment. Using this information and a time interval of 
three months, possible multiple positive culture results or notifications concerning 
the same patient are merged into a single case either by a notifying laboratory or 
after the notification is received in the NIDR database. Data from this population-
based laboratory surveillance system formed the basis for data collection for all of 
the studies presented.  
4.2 Study population and case definitions  
A case of invasive IPI (I-IV) was defined as an illness in which S. pneumoniae was 
isolated from blood or CSF or both during 1995-2002 and reported to the NIDR. Of 
a total of 4611 IPI episodes identified from primary diagnostic laboratory, only the 
first episode of each case-patient was included in the analysis (n = 4357); recurrent 
episodes and those lacking identifying information were excluded. Cases with S. 
pneumoniae bacteremias (SPBs) were defined as the isolation of S pneumoniae from 
blood only; cases with S. pneumoaniae meningitis (SPMs) included those in which 
S.  pneumoniae was isolated from CSF with or without SPB within seven days of 
each other. 
For the evaluation of the burden of NPB (IV), data on IPI patients’ 
hospitalizations obtained seven or fewer days prior to the first positive blood culture 
specimen for S. pneumoniae were retrieved from the National Hospital Discharge 
Register (HILMO) by using each case-patient’s unique national identity code for 
database linkage. Information on hospitalizations was available for 4217 (96.8%) of 
IPI case-patients, of which 3973 were bacteremias. Pneumococcal bacteremia was 
defined as nosocomial if the first positive blood culture was obtained more than two 
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days after admission, or if the patient had been hospitalized for more than two days 
during the seven days prior to the first positive blood culture.  
4.3 Controls (III) 
For each case, ten controls matched on age (same year of birth if possible, otherwise 
± 1 year), gender, and place of residence were randomly selected from the 
Population Information System. 
4.4 Definitions and ascertainment of underlying medical  conditions     
(II-IV) 
To obtain information on comorbidities and underlying conditions for which PPV23 
is recommended (Appendix 1), we linked the IPI surveillance database to the 
following national population-based registries using the date of the first positive 
specimen for S. pneumoniae and the patient’s unique national identity code: the 
Cancer Registry (diagnosis of hematological and non-hematological malignancy 
within one year or five years prior to the specimen date), NIDR (HIV infection), 
National Social Insurance Institution (KELA), and HILMO. Each HILMO record 
includes each patient’s identifying information, admission and discharge dates, 
healthcare provider, type of service, medical specialty, place (home or institution) 
from which he or she was transferred to the facility, and data on surgical procedures 
and discharge diagnoses. Data were coded according to the International 
Classification of Diseases (ICD) 9th or 10th Revision (since 1996). The presence of 
the following chronic underlying diseases was defined as a KELA record indicating 
entitlement for reimbursement of medication expenses related to diabetes mellitus, 
chronic pulmonary disease (COPD and asthma), congenital or acquired 
immunodeficiency, rheumatic and other autoimmune diseases requiring 
immunosuppressive therapy, solid organ and bone marrow transplantation, cardiac 
failure, and renal failure. Alcohol-related diseases (ARDs), chronic liver diseases, 
diseases of the spleen, and CSF leakage were defined as a record in HILMO 
with one or more ICD discharge diagnoses within one year prior to the first 
positive specimen date (Appendix 2).  
In the population-based case-control study (III), patients with chronic pulmonary 
disease were identified among those entitled to special reimbursement of medication 
expenses for asthma or COPD in the KELA database or who had a record of being 
hospitalized for these conditions during the 12 months prior to the IPI episode 
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registered in the HILMO database. The criteria for KELA reimbursement include a 
physician’s certificate indicating the diagnosis and severity of the disease, including 
lung function tests and the need for drug treatment lasting at least six months. In the 
KELA database, asthma and COPD share the same reimbursement group code and 
cannot be separated. Because of restrictions on persons aged 50 years or younger, 
we considered all such individuals as having medicated asthma and no COPD. A 
total of 190 (8.6%) cases with asthma or COPD or both, and 702 (3.2%) controls 
were identified in the KELA database. Persons at low risk for asthma (LRA) were 
defined as those meeting the KELA reimbursement criteria for asthma or COPD or 
both, but with no record of hospitalization for these conditions in the 12 months 
prior to the IPI episode. High-risk asthma (HRA) was defined as at least one 
hospitalization with an ICD-9 or ICD-10 coded primary diagnosis (Appendix 2) for 
this condition in the previous 12 months. 
4.5  Clinical outcome of pneumococcal infection (II-IV) 
The vital status (possible date of death) at 7, 28, and 90 days from the first positive 
culture of S. pneumoniae for each case-patient was determined from the National 
Population Information System by use of the national identity codes. 
4.6 Blood and cerebrospinal fluid activity (I) 
Information about the annual numbers of blood culture and CSF sets processed 
during the study period were obtained through a survey of all clinical microbiology 
laboratories that had reported any bacterial isolation from blood or CSF to the NIDR 
during 1995-2002. International guidelines require that the blood specimen 
collection method include obtaining blood in two pairs of aerobic and anaerobic 
bottles (approximately 10 ml and 5 ml per bottle for adults and children, 
respectively) from two different sites (235). Blood and CSF culturing rates were 
expressed as the number of culture sets processed per 100 000 population, and the 
yield of SPB or SPM as cases per 1000 blood or CSF cultures. One HCD was 
excluded from the analysis because the laboratory data on isolations of S. 
pneumoniae from blood were incomplete. 
  46
4.7 Serotyping and antimicrobial susceptibility (I, III-IV) 
As described previously, Streptococcus pneumoniae isolates sent to the reference 
laboratory at KTL as a part of national surveillance during 1995-2002 were serotyped 
using pneumococcal antisera (236). Pneumococcal serotypes were grouped as follows: 
PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F), 10-valent PCV serotypes (adding 
serotypes 1, 5, and 7F), 13-valent PCV serotypes (adding serotypes 3, 6A, and 19A), 
PPV23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 23F, and 33F), and all other serotypes/groups. From 1995 to 1999, 
serogroups 10, 11, 12, 15, 17, and 33 remained untested for type level, and since 2000, 
serogroups 11, 12, and 15 have been tested for type level. As described previously, 
antimicrobial susceptibility testing was performed using Clinical and Standard 
Laboratory Institute methods (237). 
4.8 Calculation of incidence rates and statistical analyses 
For the study of trends and geographical variation in IPI in Finland (I), 
population data from Statistics Finland for 1995-2002 served as denominators to 
calculate age- and gender-specific incidence rates as well as rates of blood and CSF 
culturing. Average annualized incidence rates during the surveillance period were 
calculated by using the total number of cases and population during 1995-2002. To 
evaluate secular trends, age- and gender-specific rates were calculated for each 12-
month period from January 1995 to December 2002. Blood and CSF culturing rates 
were expressed as the number of culture sets processed per 100 000 population, and 
the yield of SPB or SPM as cases per 1000 blood or CSF cultures. Poisson 
regression models served to assess whether observed changes in annual incidence 
rates over time were statistically significant. The chi-squared test and chi-squared 
test for trends served to assess statistical significance in cross-tabulated data. P < 0.05
were considered significant. The Spearman correlation coefficient and P values were 
calculated for the relationship between regional rates of SPB and SPM as well as
between rates of blood and CSF cultures processed, respectively.  
In the study of IPI and all-cause mortality among persons with and without 
chronic medical conditions (II), the population at risk in person-years for disease 
specific categories was obtained from corresponding national healthcare registries. 
Male-to-female rate ratios with 95% confidence intervals (CI) were also calculated.  
Categorical variables were analyzed with the χ2 test or with Fisher’s exact test. 
Continuous variables were analyzed with the Mann-Whitney U test. P< 0.05 was 
considered statistically significant.  
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For the population-based case-control study of chronic pulmonary diseases and 
the risk of IPI (III), data from KELA on the total number of persons entitled to 
reimbursement for chronic lung disease medications during 1995-2002 served as the 
denominator to calculate the average annualized incidence of IPI among persons 
with chronic lung disease. To identify independent factors associated with IPI and to 
control for confounding, we used a conditional logistic regression model. Chronic 
lung disease was the main variable of interest and the covariates included appear in 
Appendix 1. The likelihood ratio test served to assess the significance of each 
covariate. Matched Odds Ratios (mOR) and 95% CIs were calculated to compare 
risk factor characteristics between cases and controls. Adjusted population 
attributable risks (PAR) for the independent risk factors in the model were 
calculated as described previously (238).  
In the study of NPB (IV), we calculated average annualized incidence rates during 
the surveillance period by using population data from Statistics Finland and the total 
number of patient-days from HILMO during 1995-2002 as denominators. The χ2 test 
or Fisher’s exact test served to assess statistical significance for categorical 
variables, and the Mann-Whitney U test for continuous variables. P< 0.05 was 
considered statistically significant. Relative risks (RR) and 95% CIs were calculated 
to compare patient and disease characteristics between NPBs and community-
acquired pneumococcal bacteremias (CAPBs); the RRs were adjusted by 
multivariable logarithmic binominal regression. Univariate and multivariable 
logistic regression served to assess the association of patient and disease 
characteristics with the outcome of death within 28 days (all-cause mortality). To 
estimate the hazard ratio of progression to death while adjusting for covariates, we 
used the Cox proportional hazard regression model in which age was treated as a 
continuous variable. 
4.9 Ethical aspects 
Research use of data from population-based registries was authorized by the 
Ministry of Social Affairs and Health, the Finnish Data Protection Authority, and the 
National Research and Development Center for Welfare and Health. Because the 
studies were exclusively laboratory- and register-based, no ethics committee 
approval was required. 
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5 RESULTS 
5.1  Overall rates of invasive pneumococcal infections (I) 
During 1995-2002, a total of 4357 cases of IPI were identified (average annualized 
incidence, 10.6 cases per 100 000 population). The median age of the IPI cases was 
52.6 years (range, 0-98 years) and 2536 (58.2%) were males; 4106 (94.2%) were 
SPBs (median age, 53.1 years; proportion males, 58.3%) and 251 SPMs (median 
age, 47.9 years; males 56.6%). 
The overall annualized incidence of SPB was 9.9 cases per 100 000 population, and 
was higher for males than for females. Rates were highest at extremes of age (Table 
5a, 5b) and increased by age in adult age groups. In children aged one year, the rate 
of bacteremia was more than twice as high as for children aged less than one year. 
The overall annualized SPM incidence was 0.6 cases per 100 000 population. The 
annualized rate of meningitis was highest among children aged under one year (3.9 
per 100 000 population), nearly twice the rate among one-year-olds (Table 6a, 6b). 
Rates of meningitis did not differ by gender. 
Table 5a. Annual incidence of Streptococcus pneumoniae bacteremia in males by 
age, Finland, 1995-2002 
Age 
group 
Annual incidence in males (cases per 100 000) Change 
(years) 1995 1996 1997 1998 1999 2000 2001 2002 1995-
2002 
(%)a P value 
< 1 21.8 16.2 30.0 27.6 27.3 30.9 31.5 24.6 26.1 38.0 0.4 
1 42.4 62.2 41.8 53.2 34.5 68.1 58.2 76.8 54.4 50.2 0.1 
2-4 12.0 12.0 15.3 8.3 10.7 13.3 15.8 17.1 13.0 37.0 0.3 
5-17 1.9 3.3 3.5 2.5 3.0 3.2 2.3 2.4 2.7 -6.1 0.8 
18-34 4.5 3.9 6.2 5.7 8.6 4.8 7.6 4.8 5.7 32.3 0.1 
35-49 8.7 8.8 12.5 13.5 12.6 12.4 10.1 12.4 11.3 26.9 0.06 
50-64 10.6 12.3 15.6 15.4 13.2 16.4 14.8 17.7 14.6 41.9 0.08 
65-74 16.6 26.5 29.8 22.2 20.0 23.9 22.1 22.9 23.0 0.0 1.0 
> 75 32.0 25.8 45.0 41.5 41.0 43.2 38.7 31.1 37.4 9.5 0.6 
All 9.0 10.1 13.2 12.4 12.2 13.0 12.3 12.8 11.9 29.6 < 0.001 
a Poisson trend: (exp (time coefficient  * 7) – 1) * 100 
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Table 5b. Annual incidence of Streptococcus pneumoniae bacteremia in females by 
age, Finland, 1995-2002 
Age 
group 
Annual incidence in females (cases per 100,000) Change 
(years) 1995 1996 1997 1998 1999 2000 2001 2002 1995-
2002 
(%)a P value 
< 1 19.3 6.8 17.2 21.6 10.7 47.4 14.6 11.2 18.1 49.0 0.4 
1 47.0 29.2 60.9 51.5 53.8 49.7 50.8 51.0 49.0 20.8 0.5 
2-4 12.4 8.3 11.6 6.5 11.1 11.5 16.4 19.1 12.1 85.2 0.06 
5-17 1.2 3.2 1.5 0.5 1.2 1.5 2.2 2.7 1.7 35.1 0.5 
18-34 2.1 2.3 3.2 2.9 3.8 3.1 4.4 3.9 3.2 86.5 0.02 
35-49 1.5 3.2 7.0 5.0 5.4 6.3 8.4 5.7 5.3 139.9 < 0.001 
50-64 7.1 6.4 6.8 8.3 8.4 8.4 10.3 9.5 8.2 52.2 0.02 
65-74 15.5 10.4 12.4 14.2 13.9 11.5 16.4 17.2 13.9 26.0 0.2 
> 75 16.2 18.7 26.5 28.0 25.3 23.6 30.6 23.1 24.1 38.0 0.03 
All 6.1 6.0 8.3 8.0 8.2 8.3 10.5 9.2 8.1 58.7 < 0.001 
a Poisson trend: (exp (time coefficient  * 7) – 1) * 100 
 
5.2.  Temporal trends and geographic variation in rates of invasive
 pneumococcal infection (I) 
The overall annual IPI rate during the study period increased significantly from 8.2 
to 11.5 cases per 100 000 population (35.1%, Poisson trend, P< 0.001). Most of this 
increase stemmed from an increase in SPB rates, particularly among persons aged 2-4, 
18-64, and more than 75 years. No significant trend was observed for SPM (Tables 
6a, 6b).  
The overall annualized incidence of IPI varied from 7.9 to 15.1 per 100 000 
population among different HCDs. Geographical variation was observed in both 
SPB rates and SPM rates.  
During the study period, a total of 1 319 222 blood culture sets and 46 907 CSF 
culture sets were processed in 30 microbiology laboratories. The annual national 
blood culturing rate increased between 1995 and 2002 (29.6%, Poisson trend,         
P< 0.001); no significant change occurred in annual CSF culture rates.                            
The higher incidence of SPB was significantly associated with the higher blood 
culturing intensity in HCD (Spearman rank correlation coefficient 0.55, P= 0.015). 
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However, we found no correlation between the incidence of SPM in HCD and CSF 
culturing intensity (Spearman rank correlation coefficient 0.36, P= 0.12). In 
addition, a statistically significant association arose between the increase in 
incidence of SPB and blood culture rates over time during the study period 
(Spearman rank correlation coefficient 0.81, P= 0.015).  
 
Table 6a. Annual incidence of Streptococcus pneumoniae meningitis in males by 
age, Finland, 1995-2002 
Age 
group 
Annual incidence in males (cases per 100,000) Change 
(years) 1995 1996 1997 1998 1999 2000 2001 2002 1995-
2002 
(%)a P 
value 
< 1 3.1 3.2 3.3 0.0 10.3 3.4 0.0 3.5 3.4 -5.4 1.0 
1 0.0 0.0 0.0 6.7 3.5 3.4 3.4 0.0 2.1 193.9 0.4 
2-4 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -100 1.0 
5-17 0.5 0.7 0.5 0.0 0.2 0.0 0.0 0.0 0.2 -97.1 0.02 
18-34 0.7 0.5 0.3 0.2 0.0 0.4 0.9 0.0 0.4 -50.3 0.4 
35-49 0.3 1.5 0.8 1.0 1.0 1.0 1.0 0.5 0.9 0.0 1.0 
50-64 1.0 1.4 0.9 1.7 0.6 1.2 0.8 1.4 1.1 -5.4 0.9 
65-74 1.1 1.1 0.0 0.5 0.0 1.0 0.5 1.0 0.7 -7.4 0.9 
> 75 2.2 1.1 1.1 1.0 1.0 0.9 0.0 0.9 1.0 -71.6 0.3 
All 0.7 1.0 0.6 0.8 0.6 0.8 0.7 0.6 0.7 -29.5 0.2 
a Poisson trend: (exp (time coefficient  * 7) – 1) * 100 
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Table 6b. Annual incidence of Streptococcus pneumoniae meningitis in females by 
age, Finland, 1995-2002 
Age 
group 
Annual incidence in females (cases per 100,000) Change 
(years) 1995 1996 1997 1998 1999 2000 2001 2002 1995-
2002 
(%)a P 
value 
< 1 16.3 6.8 0.0 0.0 7.1 0.0 0.0 3.7 4.4 -92.8 0.03 
1 9.4 0.0 0.0 0.0 0.0 0.0 3.6 3.6 2.2 -65.7 0.5 
2-4 0.0 0.0 2.1 1.1 1.1 0.0 0.0 1.2 0.7 34.2 0.8 
5-17 0.5 0.2 0.0 0.0 0.2 0.2 0.0 0.3 0.2 -59.5 0.5 
18-34 0.4 0.4 0.2 0.0 0.2 0.0 0.0 0.0 0.1 -97.2 0.04 
35-49 0.2 0.3 0.7 0.3 0.4 0.2 0.9 0.5 0.4 108.5 0.3 
50-64 0.7 0.9 0.7 0.6 1.4 0.6 1.0 0.8 0.8 11.9 0.8 
65-74 0.4 1.2 1.6 0.8 1.2 0.8 0.8 0.0 0.9 -47.1 0.4 
> 75 0.5 0.9 0.0 0.5 0.0 0.4 0.4 0.8 0.4 20.8 0.9 
All 0.7 0.6 0.5 0.3 0.6 0.3 0.5 0.5 0.5 -29.5 0.2 
aPoisson trend: (exp (time coefficient  * 7) – 1) * 100 
5.3 Influence of underlying medical conditions (II-III) 
Overall, 2302 (52.8%) of the 4357 cases presented at least one underlying condition, 
including age 65 years or older, for which PPV23 is recommended. Among 
working-age patients aged 18-64 years, however, only 799 (36.1%) had a current 
indication of PPV23. Of patients aged 18-49 and 50-64 years, 372 (29.0%) and 427 
(45.7%), respectively, exhibited a condition for which PPV23 is currently 
recommended. Among those of working-age, ARDs, chronic pulmonary disease, 
and diabetes mellitus were the most common vaccine indications, whereas chronic 
pulmonary disease, cardiac failure, and diabetes mellitus were the most common 
among elderly patients (Table 7). Persons aged 18-64 years accounted for 96.0% of 
cases with ARDs. The highest rates of IPI occurred in patients with hematological 
malignancy and organ or bone marrow transplantation.  
Of the 1282 total IPI cases aged 18-49 years, all were included in the case-control 
study. Overall, 359 (28.0%) case-patients (compared with 743 (5.8%) of control-
subjects) presented an underlying medical condition for which PPV23 is 
recommended. Of these case-patients, 77 (6.0%) LRA (compared with 302 (2.4%) 
of the controls), 14 (1.1%) case-patients, and 12 (0.1%) of the controls had HRA 
(Table 8). The incidence of IPI among persons aged 18-49 years with LRA was 18.2 per 
100 000 annually. Only four (0.3%) case-patients and none of the controls had  
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a record of hospitalization for COPD in the previous 12 months. Of the 77 patients 
with LRA, ten (13.0%) presented one or more additional conditions for which 
PPV23 is recommended. No patients with HRA exhibited other conditions. In a 
conditional logistic regression model adjusted for other risk factors, case-patients 
were more likely than controls to have HRA and LRA. The adjusted population-
attributable risks (PARs) for HRA and LRA were 0.010 (95%CI, 0.0035-0.017) and 
0.039 (95%CI, 0.023-0.055), respectively. 
5.4 Burden of nosocomial pneumococcal bacteremia (IV) 
During the study period, 387 patients with NPB were identified (43-53 cases per 
year), representing approximately 9.7% of the 3973 hospitalized SPB cases (range 
by year, 8-14%). The average annualized NPB incidence rate was 0.9 cases per 100 000 
population (range by year, 0.8-1.0; range by tertiary care region, 0.7-1.2) and 0.66 
cases per 100 000 patient-days (range by year, 0.60-0.73; range by tertiary care 
region, 0.49-0.95).  
Many characteristics of patients with NPB differed from those with CAPB in 
univariate analysis (Table 9). Patients with NPB were significantly older than patients 
with CAPB (median age, 67.3 vs. 51.6 years; P< 0.001). Of the patients with NPB, 
229 (59.2%) presented at least one underlying condition (other than age 65 or older) 
for which PPV23 is currently recommended, compared with 1241 (34.6%) of the 3586 
patients with CAPB (P< 0.001). This difference was due to significantly greater 
proportions of chronic pulmonary disease, cardiac failure, diabetes mellitus, ARD, 
non-hematological and hematological malignancies, and immunodeficiency or 
rheumatic diseases among patients with NPB. Among the 152 NPB cases aged 16-64 
years, 113 (74.3%) had at least one underlying condition for which PPV23 is 
recommended. Characteristics independently associated with higher risk for NPB in 
the logarithmic binominal regression model included male gender, increasing age, 
malignancies, chronic liver disease, ARD, and chronic pulmonary disease.  
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5.5  Clinical outcome of invasive pneumococcal infections 
Of the total 4357 IPI cases, 202 (4.6%) died on the day of admission, 373 (8.6%) died 
within one week, and 536 (12.3%) within 28 days. An additional 130 cases died 
between 29 and 90 days after the first blood- and/or CSF-culture positive for S. 
pneumoniae. During hospitalization for IPI, 437 (10.0%) cases died. The in-hospital 
case-fatality proportions (CFPs) at 7, 28, and 90 days were 7.9%, 10.2%, and 10.7%, 
respectively. Of all the deaths during the first month, persons aged 18-49 and 50-64 
years accounted for 124 (23.1%) and 130 (24.2%), respectively; CFPs in these groups 
were 9.7% and 13.9%, respectively. The CFPs at 7, 28, and 90 days were similar for 
both genders among those aged 18-49 years, but significantly higher in men than in 
women among those aged 50-64 years at 28 and 90 days (16.8% vs. 9.0% and 21.4% 
vs. 12.4%; P< 0.01 for both comparisons). The CFPs at days 28 and 90 were 
significantly higher for meningitis than for bacteremia (P< 0.02).  
The highest CFPs at 28 days occurred among persons with non-hematological 
malignancy, ARD, and cardiac failure (Table 7). Of those cases aged 18-64 
years who died on the day of culture or during the first week, the median ages 
were 50.2 and 48.7 years, respectively; the most common underlying medical 
conditions were ARDs, diabetes, and immunodeficiency/rheumatic diseases in 
both groups. Of the fatal cases among persons aged 18-49 years and 50-64 years, 
61 (49.2%) and 76 (58.5%), respectively, exhibited an underlying condition 
considered an indication of PPV23. The CFP for patients aged 18-64 years with 
a vaccine indication was 17.1%, compared with 8.5% for patients with no such 
indication (relative risk (RR), 2.1; 95%CI, 1.6-2.6). Of the case-patients with 
LRA in the case-control study, seven (9.1%) died within 28 days. All but one death 
occurred within seven days; no cases with HRA died. 
Of the NPB cases, 121 (31.3%) died within 90 days of the first positive blood 
culture. Of these deaths, 67 (55.4%) occurred within 7 days, and 92 (76.0%) within 
28 days; 88 (72.7%) were aged 65 years or older. The overall CFPs at 7, 28, and 90 
days were significantly higher in NPB than in CAPB cases (17.3% vs. 7.6%, 23.8% 
vs. 10.8%, and 31.3% vs.13.4%, respectively; P< 0.001 for all comparisons). In 
males, CFPs were nearly 1.5 times higher than in females, and were almost twice as 
high among the elderly as among patients aged 16-64 years (Table 10). CFPs were 
highest among patients with non-hematological malignancies, cardiac failure, 
ARDs, hematological malignancies, and immunodeficiency or rheumatic diseases. 
Factors significantly associated with death within 28 days of positive blood culture 
(all-cause mortality) in univariate analyses included increasing age and cardiac 
failure. After adjusting for age and gender in the multivariable logistic regression 
model, patient characteristics that independently predicted death within 28 days 
56
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included immunodeficiency or rheumatic diseases (P= 0.004) and ARDs (P= 0.014). 
To evaluate the outcome of all-cause mortality after NPB, we used a Cox 
proportional hazard regression model. In addition to the variables identified in 
multivariable logistic regression, non-hematological and hematological 
malignancies independently increased the risk (hazard) of death. 
 
 
Table 10. Characteristics associated with death in patients  
with nosocomial pneumococcal bacteremia, Finland, 1995-2002 
Deaths (case fatality proportion, %)  
Characteristic At day 7  At day 28  At day 90  
Age group    
< 16 years 0 (0) 0 (0) 0 (0) 
16-64 years 18 (11.8) 23 (15.1) 33 (21.7) 
> 64 years 49 (22.8) 69 (32.1) 88 (40.9) 
All 67 (17.3) 92 (23.8) 121 (31.3) 
Gender    
Male 47 (19.5) 65 (27.0) 86 (35.7) 
Female 20 (13.7) 27 (18.5) 35 (24.0) 
Underlying conditiona    
Chronic pulmonary disease 14 (20.9) 21 (31.3) 24 (35.8) 
Cardiac failure 15 (26.8) 20 (35.7) 25 (44.6) 
Diabetes mellitus 9 (20.0) 13 (28.9) 16 (35.6) 
Immunodeficiency/rheumatic diseases 10 (26.3) 14 (36.8) 16 (42.1) 
Non-hematologic malignancy 11 (29.7) 13 (35.1) 19 (51.4) 
Alcohol-related disease 9 (27.3) 11 (33.3) 14 (42.4) 
Hematologic malignancy 7 (26.9) 8 (30.8) 11 (42.3) 
Chronic liver disease 1 (20.0) 1 (20.0) 2 (40.0) 
Organ/bone marrow transplantation 0 (0) 0 (0) 0 (0) 
Chronic renal failure 0 (0) 0 (0) 0 (0) 
≥ 1 underlying condition 48 (71.6) 66 (71.7) 85 (70.2) 
aPatient may have more than one underlying condition 
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5.6 Pneumococcal serotypes and the proportion of potentially   
 vaccine-preventable infections (I, III-IV)        
We serotyped a total of 4056 (93.1%) S. pneumoniae isolates from patients with IPI 
and estimated the proportion of potentially vaccine-preventable pneumococcal 
infections with currently available and investigational vaccines.  
 
1) PPV23 
Of all pneumococcal isolates, 3395 (83.7 %) were serotypes/serogroups included in 
PPV23; 1806 (88.9%) were among nonelderly adults aged 18-64 years, and 1110 
(86.0%) were among patients aged 65 years or older (Table 11b). In the case-control 
study (III), 1056 (82.4%) of the isolates were serotyped, and PPV23 coverage was 
92.9% among patients with chronic lung disease. In the NPB study (IV), a total of 
319 (82.4%) S. pneumoniae isolates were available for serotyping. Of the 
pneumococcal isolates, 228 (71.5%) were serotypes included in PPV23. 
2) PCV7 
The serotypes included in PCV7 accounted for 2131 (52.5%) of all pneumococcal 
isolates available for serotyping. Of the 573 pneumococcal isolates among children 
under the age of five, 400 (69.8%) were serotypes included in PCV7. The serotype 
coverage was highest among children aged one to four years (74.1%); among those 
aged two to eleven months, serotype coverage was 59.0% (Table 11a). In adult age 
groups, serotype coverage was 48.2% and 51.6% among IPI cases aged 18-64 years 
and 65 or older, respectively. Among cases with chronic pulmonary disease (III), 44 
(54.3%) of the isolates were serotypes included in PCV7, and 147 (46.1%) in the 
study of nosocomial pneumococcal bacteremia (IV). 
3) 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10 and 
PCV13) 
The serotypes included in PCV10 and PCV13 accounted for 2524 (62.2%) and 3156 
(77.8%) of all serotyped isolates of S. pneumoniae, respectively (Tables 11a and 
11b). Among those groups aged 5, 18-64 and 65 years or older, serotype coverage 
was 75.9% vs. 91.3%, 60.4% vs. 74.8%, and 57.4% vs. 75.9%, respectively. Among 
cases with chronic pulmonary disease (III), serotype coverage for PCV10 was 
72.8%, and for PCV13, 79.0%. 
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Table 11a. The most common serotypes of S. pneumoniae in invasive infections 
among children, Finland, 1995-2002 
Number of isolates among children (%)  
Individual serotypea < 1 year 1 year 2-4 years 5-17 years Total 
6B 22 (15.2) 56 (23.0) 36 (19.5) 10 (6.2) 124 (16.9) 
14 18 (12.4) 59 (24.3) 31 (16.8) 10 (6.2) 118 (16.1) 
19A 21 (14.5) 18 (7.4) 15 (8.1) 4 (2.5) 58 (7.9) 
18C 7 (4.8) 17 (7.0) 17 (9.2) 16 (9.9) 57 (7.8) 
7F 14 (9.7) 9 (3.7) 8 (4.3) 25 (15.5) 56 (7.6) 
23F 12 (8.3) 18 (7.4) 12 (6.5) 13 (8.1) 55 (7.5) 
19F 11 (7.6) 20 (8.2) 15 (8.1) 8 (5.0) 54 (7.4) 
4 6 (4.1) 8 (3.3) 14 (7.6) 19 (11.8) 47 (6.4) 
6A 7 (4.8) 10 (4.1) 11 (5.9) 6 (3.7) 34 (4.6) 
9V 7 (4.8) 7 (2.9) 7 (3.8) 11 (6.8) 32 (4.4) 
Other 
serotypes/groups 
20 (13.8) 21 (8.6) 19 (10.3) 39 (24.2) 99 (13.5) 
All serotypes 145 (19.8) 243 (33.1) 185 (25.2) 161 (21.9) 734 (18.1) 
Serotypes included in vaccines 
7-valent 83 (57.2) 185 (76.1) 132 (71.3) 87 (54.0) 487 (66.3) 
10-valent 97 (66.9) 194 (79.8) 144 (77.8) 121 (75.2) 556 (75.7) 
13-valent 127 (87.6) 225 (92.6) 171 (92.4) 135 (83.9) 658 (89.6) 
aAll serotypes constituting at least 2% of all cases are listed individually 
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Table 11b. The most common serotypes of S. pneumoniae in invasive infections 
among adults, Finland, 1995-2002 
Number of isolates (%) among adults  
Individual serotypea 18-34 years 35-49 years 50-64 years 65-74 years ≥ 75 years Total 
4  90 (22.9) 140 (18.3) 120 (13.7) 77 (12.8) 66 (9.6) 493 (14.8) 
14 42 (10.7) 73 (9.5) 106 (12.1) 60 (10.0) 94 (13.6) 375 (11.3) 
3 14 (3.6) 90 (11.7) 94 (10.8) 70 (11.6) 62 (9.0) 330 (9.9) 
7F 75 (19.1) 72 (9.4) 62 (7.1) 37 (6.2) 34 (4.9) 280 (8.4) 
23F 21 (5.3) 29 (3.8) 56 (6.4) 52 (8.7) 68 (9.9) 226 (6.8) 
9V 34 (8.7) 54 (7.0) 44 (5.0) 29 (4.8) 30 (4.4) 191 (5.7) 
6B 8 (2.0) 22 (2.9) 39 (4.5) 26 (4.3) 47 (6.8) 142 (4.3) 
19F 6 (1.5) 13 (1.7) 29 (3.3) 35 (5.8) 47 (6.8) 130 (3.9) 
22F 15 (3.8) 24 (3.1) 39 (4.5) 18 (3.0) 33 (4.8) 129 (3.9) 
6A 4 (1.0) 15 (2.0) 34 (3.9) 21 (3.5) 34 (4.9) 108 (3.3) 
9N 8 (2.0) 20 (2.6) 35 (4.0) 16 (2.7) 24 (3.5) 103 (3.1) 
8 9 (2.3) 39 (5.1) 24 (2.7) 14 (2.3) 9 (1.3) 95 (2.9) 
19A 10 (2.5) 13 (1.7) 18 (2.1) 25 (4.2) 26 (3.8) 92 (2.8) 
18C 9 (2.3) 17 (2.2) 27 (3.1) 16 (2.7) 18 (2.6) 87 (2.6) 
Other 
serotypes/groups  
48 (12.2) 145 (18.9) 146 (16.7) 105 (17.5) 97 (14.1) 541 (16.3) 
All serotypes 393 (11.8) 766 (23.1) 873 (26.3) 601 (18.1) 689 (20.7) 3322 (81.9) 
Serotypes included in vaccines 
7-valent 210 (53.4) 348 (45.4) 421 (48.2) 295 (49.1) 370 (53.7) 1644 (49.5) 
10-valent 298 (75.8) 439 (57.3) 490 (56.1) 336 (55.9) 405 (58.8) 1968 (59.2) 
13-valent 326 (83.0) 557 (72.7) 636 (72.9) 452 (75.2) 527 (76.5) 2498 (75.2) 
23-valentb  370 (94.1) 675 (88.1) 761 (87.2) 512 (85.2) 598 (86.8) 2916 (87.8) 
23-valentc  359 (91.3) 636 (83.0) 707 (81.0) 485 (80.7) 565 (82.0) 2752 (82.8) 
a All serotypes constituting at least 2% of all cases are listed individually; b all serogroups included in the PPV23 
vaccine; c excluding serogroups 10, 11, 12, 15, 17, and 33, none of which were serotyped 
 
5.7  Antimicrobial susceptibility 
Antimicrobial susceptibility testing results were available for 138 (35.7%) 
nosocomial S. pneumoniae isolates: six isolates (4.3%) were resistant to 
erythromycin, and five (3.6%) were intermediately resistant to penicillin; no 
patients with a nonsusceptible isolate died within 28 days.  
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6 DISCUSSION 
The studies in this thesis provide baseline data on the epidemiological characteristics 
of IPIs from eight years of population-based surveillance in Finland. The 
surveillance system in Finland offers nationwide and comprehensive data on IPI. 
Linking IPI data collected with data available in national healthcare registries as 
well as other databases enabled us to more accurate define the pneumococcal disease 
burden and to identify the most important risk factors. This information is of 
particular interest as public health authorities in Finland prepare for the introduction 
of routine childhood immunization with pneumococcal conjugate vaccines, which 
will likely occur in 2010. This new key information contributed by the original 
studies includes documenting an increase by one third in the incidence of IPI during 
the study period and showing that these temporal and regional increases were 
associated with higher blood culturing rates (I). This indicates that the true incidence 
of SPB in Finland is likely higher than previously estimated; confirming the 
substantial burden of IPI among non-elderly adults without established underlying 
medical conditions that are indications for PPV23; two-thirds of IPIs and one half of 
fatal cases occurred in persons without a recognized PPV23 indication (II);  
providing confirmatory evidence for recent findings in other studies that both HRA 
and LRA are independent risk factors for IPI (III); and, for the first time, we 
quantify the impact of healthcare-associated pneumococcal bacteremia from 
nationwide surveillance data, thus documenting that  mortality was more than 
double that of CAPB (IV). This thesis also discusses the public health policy 
implications of these findings.  
6.1  Overall rates of invasive pneumococcal infections in Finland (I) 
The overall rates of IPI in Finland during the study period were similar to those of 
previous reports from other European countries (8, 9, 240, 241) and from California, 
USA (70). Consistent with other reports, this study also shows a bimodal age-related 
variation in the incidence of IPI, with small children and persons aged 65 years and 
older suffering the highest rates. Previous reports have also described differences in 
incidence by gender (6, 8, 9, 70, 85). However, the incidence of invasive infections 
among infants under two in our study and in other European studies is significantly 
lower than reported rates from studies in the USA before the introduction of 
pneumococcal conjugate vaccine (8, 10, 90). This study provides evidence that these 
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differences in disease rates may at least partly stem from differences in blood 
culturing rates, diagnostic and admission practices – particularly the practice of 
outpatient blood culturing – and the treatment of young children with occult 
bacteremia in the USA. According to clinical practice guidelines in Finland, blood 
cultures are obtained only if the child with febrile illness is hospitalized. 
Interestingly, no comparative data are available about the relation of blood culturing 
rates and SPB in children from the USA. A significant increase in the annual rate of 
IPI during the study period was detected among both genders and was attributed to 
an increase in the rate of bacteremia over time among both. As we calculated rates 
for calendar years, some of the year-to-year variation in rates may be related to the 
well-documented seasonality of pneumococcal disease and to variations in the 
incidence of respiratory virus circulation, including seasonal influenza and 
respiratory syncytial virus (128, 242, 243).  
The incidence of SPM was highest in children under one year, and the age-specific 
rates were similar to those found in other studies from developed countries (119, 
244). In contrast to the SPB rate, the rate of SPM remained relatively constant 
during the study period. Similarly, increasing trends in the rates of bacteremia and 
largely stable SPM rates have been reported from Denmark during 1989-1994, 
Sweden, Norway, the UK, Scotland, and South Carolina, USA (79, 87-89, 119) 
conceivably because the diagnostic practice for meningitis may vary less than for 
pneumonia and bacteremia. In contrast, decreasing observed rates of SPB were 
reported from Denmark during 1995-1999 (90).  
6.2 Temporal trends and geographical variation in invasive 
pneumococcal infection rates (I) 
Previous reports from England and Wales (8, 9) and from South Carolina, USA, (79) 
also suggested that higher rates of blood culture sampling were associated with a 
higher incidence of pneumococcal infections. In Sweden, however, no increase in 
IPI incidence was correlated with an increase in blood culture sampling rates (241). 
Our data indicate that the regional variation and secular rise in the incidence of SPB 
were associated with blood culture sampling rates. Although the introduction of 
electronic laboratory reporting during the study period has improved the timeliness 
and thouroughness of surveillance data, the change from mail to electronic reporting 
showed no correlation with an observed increase in bloodstream infections in 
Finland (83).  
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6.3 Influence of underlying medical conditions (II) 
In our study, almost two-thirds of IPI cases among working-age adults exhibited 
none of the underlying conditions for which PPV23 is recommended. This 
proportion is substantially higher than that previously reported from the USA (41%) 
(10, 245), but few comparable data are available from European countries. As in 
previous studies, ARD was the most frequent (10.9%) underlying condition in the 
working-age group (246). The incidence of IPI among persons with ARD in our 
study, however, was lower (21.9) than estimates from the USA and Scotland, 
ranging from 62.0 to 483.4 per 100 000 population in previous population-based 
studies (11, 75, 132). Because of the lower baseline incidence in Finland, however, 
difficulties in defining the population at risk for ARD, as well as evaluating the 
accuracy and representativeness of the denominator data used in these studies, 
interpretation of the observed differences is complex. Our estimated denominator for 
ARD was an extrapolation based on the 12-month prevalence of persons with 
alcohol use disorders from a representative sample of the Finnish adult (30 years or 
older) population (239). 
Among patients with various immunocompromising conditions, the rate of IPI varied 
from 33.4 to 547.2 per 100 000, and was highest among those with hematological 
malignancy. Among immunocompetent patients (persons with diabetes mellitus, 
chronic pulmonary disease, and cardiac failure), rates showed less variation (range, 
12.0-47.1 per 100 000). Previous population-based studies from the USA and Scotland 
reported higher rates for solid cancer (216.1 to 300.4 per 100 000), chronic pulmonary 
disease (62.9 to 503.0 per 100 000), and HIV (422.9 to 2031.4 per 100 000) (11, 75, 
132), likely due to differences in population composition, databases, definitions, 
sources of denominator data, and the accuracy and thoroughness in identifying the 
diagnoses of underlying conditions in IPI patients. Previous studies have included 
malignancies at any point in time (11, 132), whereas we restricted those diagnosed less 
than five or one year, respectively, before the IPI episode. For chronic pulmonary 
diseases, some studies incorporated only COPD and emphysema cases (75, 132), but 
we included asthma as well. The relatively low rate of IPI among persons infected 
with HIV in Finland may reflect easier access to antiretroviral therapy, early antibiotic 
treatment without blood cultures, and the use of prophylactic antibiotics among those 
with low CD4+ T cell counts. 
Of the national registries we used to define the co-morbidities for IPI cases and to 
acquire population-based denominators, the Finnish Cancer Registry has almost 
100% coverage (247, 248), and the comprehensiveness of hospital discharge data 
has been validated previously (249-252).  
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This is the second study in which persons with asthma were found to be at increased 
risk of IPI. The observations in our study are in agreement with those of a previous 
study (173) in which persons with mostly high-risk asthma were at a 2.4-fold higher 
risk for IPI than did controls. The group of persons with asthma was heterogeneous, 
depending on factors such as the intensity and type of medication 
(immunosuppression) and the need for hospitalization. We defined HRA and COPD 
as at least one hospitalization for asthma or COPD during the 12 months prior to the 
IPI episode, whereas Talbot et al. (173) considered hospitalization optional in their 
definition of HRA, in which they defined asthma as either high- or low-risk. High-
risk patients were those who required at least one of the following: admission to a 
hospital or emergency department, intensive therapy for acute asthma attacks, long-
term corticosteroids, or the dispensing of three or more prescriptions for β-agonists 
in the year prior to enrolment in the study. The annual incidence of IPI was nearly 
two-fold (4.2 vs. 2.3 per 10 000 persons) higher among patients with HRA than 
among those with LRA. In our study, the difference in risk for IPI was even more 
pronounced between the two groups with different severeness and consequent 
medication. The ascertainment of asthma in the study by Talbot et al. (173) differed 
somewhat from ours, thus possibly resulting in our categorization of a higher 
number of evere cases of asthma or COPD in the group of high-risk patients.  
The selection of age groups differs between studies that address asthma and IPI. We 
restricted our study to non-elderly working-aged adults due to the difficulties in 
defining and diagnosing asthma in children. Not including children could explain the 
higher risk for IPI among cases with asthma in our study that that reported in Talbot 
et al. (173), which included subjects 2-49 years of age. The studybase also differed: 
our study was nationwide, population-based, and unselected, whereas that of Talbot 
et al. comprised primarily persons of low socioeconomic status enrolled in a 
Medicaid (TennCare) program. Consequently, the results may not be fully 
applicable to the entire US population. The risk of underestimating the incidence of 
HIV infection is more obvious in a population with a high prevalence of HIV 
because the HIV infection often goes undetected until a known HIV-related illness 
develops (7, 253).  
6.4 Burden of nosocomial pneumococcal bacteremia (IV) 
The study of NPB provides a comprehensive, population-based evaluation of the 
burden of NPB, highlighting how its characteristics differ from those of CAPB. Our 
estimates from national laboratory-based surveillance are representative of the entire 
population of Finland. The standard case definition minimized selection bias due to 
different case mixes, and provides accurate rates for comparison over time and 
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place. The registry-based design enabled the use of accurate denominators for NPB 
rates (i.e., total hospital patient-days) and differentiation between traditional 
nosocomial and healthcare-associated cases. Although annual rates of NPB per 100 000 
population and patient-days during the study period varied little, rates varied in 
different tertiary care regions, possibly reflecting small numbers of cases or local 
disease clusters.  
The proportion of SPBs among hospitalized nosocomial patients varied from 7.5% 
to 13.9% annually. This proportion is smaller than that previously reported from 
Spain (25%-41%) (190, 192) and the USA (27%-59%) (189, 191, 193), but similar 
to that in a report from France (10%) (196) and in recent reports from Spain (10%-
14%) (194, 195, 197). The reasons for these differences may stem not only from 
differences in study populations, the small numbers of cases from individual 
hospitals (189-195), and the case definitions used, but also from admission criteria 
and differences in blood culture sampling practices among pneumonia patients 
between those who are hospitalized and those who are outpatients.  
The definitions used in previous reports for the nosocomial acquisition of disease also 
varied; some included episodes that manifested 48 or more hours after hospitalization 
(195), whereas others used a longer, 72-hour cut-off point (193, 196, 197). In addition 
to the episodes in which the index blood culture was obtained more than two days 
after hospitalization, our analysis also included those that may have been associated 
with a previous admission in the same or other healthcare setting within a seven-day 
period. These potentially healthcare-associated infections accounted for about one-
third of nosocomial SPBs, and patient characteristics in the two groups were similar. 
The median period of hospitalization before the index blood culture (eight days) is 
consistent with that of previous reports, thus indicating that NPB tends to occur after a 
relatively prolonged period of hospitalization (195, 197).  
Patients with NPB had significantly more chronic pulmonary diseases, cardiac failure, 
diabetes mellitus, ARD, malignancies, and immunodeficiency or rheumatic disease 
than did patients with CAPB. Previous research has associated NPB with severe 
underlying conditions, including neoplasia, COPD, heart failure, and cirrhosis (197). 
A case-control study design in elderly veterans found that diagnoses of respiratory or 
hematological malignancy, anemia, COPD, and coronary artery disease on admission 
to the hospital were independent clinical predictors of NPB (193).  
6.5 Clinical outcome of invasive pneumococcal infections (II, IV) 
By linking surveillance data to national vital statistics, we were able to estimate all-
cause mortality up to three months following an episode of IPI. Although the CFP 
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was 8.6% during the first week, mortality at one month among patients with various 
underlying conditions ranged from about 5% to 30% and increased in most groups 
up to three months after the first positive culture, probably reflecting both the 
severity of the underlying illness and the effects of long-term sequelae (100). 
Overall mortality was highest for non-hematological malignancy, chronic liver 
disease, ARDs, cardiac failure, and HIV infection. Our findings are consistent with 
those of two previous population-based studies on IPI and pneumococcal bacteremic 
pneumonia in which case-fatality among persons with underlying medical 
conditions ranged from 3.3% to 13.4% (11) and from 5.8% to 33.9% (104), 
respectively. In both studies, the highest mortality rate was observed among persons 
with cirrhosis and alcohol abuse, coronary artery disease/congestive heart failure, 
and non-hematological malignancies. Definitions used to assess IPI-associated 
mortality vary: some studies evaluate all-cause mortality (193-196), whereas others 
evaluate only mortality directly attributable to IPI (197). Differences in healthcare 
delivery systems and in the length of hospital stay can influence the analysis of vital 
status at discharge (i.e., in-hospital mortality). 
All-cause mortality was significantly higher in NPB than in CAPB cases. The risk of 
death increased with age, being 34% among persons aged 65 years or older, and 
nearly 1.5 times higher among males than among females. Our time-dependent 
model showed that, in addition to age, male gender, and malignancies, risk of death 
was independently associated with immunodeficiency or rheumatic diseases and 
ARDs. Previous studies on NPB have reported much higher CFPs, ranging from 
38% to 76% (189, 190, 194). This may stem from differences in the study 
populations, as some included only adults (193, 194, 197) or elderly males (191). In 
some studies, up to 57% of NPB cases suffered malignancies (190), likely reflecting 
a selection bias in hospital-based case-ascertainment. Our data indicate that in 
studies evaluating the clinical outcome of pneumococcal infections, mortality rates 
should be stratified according to nosocomial and community-associated cases. 
6.6 Pneumococcal serotypes and the proportion of potentially 
vaccine-preventable infections (I, III, IV) 
Our data indicate that some 70% and 52% of invasive pneumococcal infections 
among children under 5 and persons 65 years and older, respectively, stemmed 
from serotypes included in currently available PCV7. About 86% of the 
serotypes/groups of pneumococcal isolates from patients aged 65 years and older 
were those included in PPV23. Among children aged five or younger, 75.9% and 
91.3% were serotypes included in PCV10 and PCV13, respectively. In the USA, 
routine childhood pneumococcal conjugate vaccine immunization has resulted in 
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dramatic reductions in rates of pneumococcal-related diseases and in major 
changes in the epidemiology of pneumococcal infections in children and adults 
(221). More than 70% of the serotypes of the pneumococcal isolates from NPB 
patients were those included in PPV23, and 74% of NPB patients aged 16-64 
years presented at least one underlying condition for which PPV23 is currently 
recommended. In Finland, PCV7 is not currently included in the national 
childhood immunization program, and despite national recommendations, the 
uptake of PPV23 among persons aged 65 years and older as well as among those 
with high-risk conditions is extremely low (203).  
6.7 Limitations 
Although the major strength of our data is the nationwide and population-based 
surveillance design over multiple years, our study also has some limitations:  
1) It is well known that ICD-coding in hospital discharge data may be incomplete 
and could be subject to misclassification. For this reason, we used hospital discharge 
data to identify only underlying conditions (ARD, chronic liver diseases, diseases of 
the spleen, and CSF leakage) for which data were unavailable in the two other 
registries that use standardized criteria and definitions. The standardized 
reimbursement criteria for underlying conditions in KELA’s database may, 
however, have excluded mild cases of certain underlying conditions such as COPD, 
asthma, and diabetes mellitus type 2. 
2) In the LRA group, we were unable to distinguish between asthma and COPD. On 
the other hand, our study population comprised non-elderly working-age persons 
where the proportion of COPD cases is likely to be extremely low.  
3) In study III, we did not have precise information about the medication of the 
case-patients and controls. Based on KELA data between 1997 and 2002, 91.2% of 
all patients entitled to special reimbursement of medication expenses for asthma or 
COPD or both (i.e., the LRA group) received medication containing inhalation or 
oral steroids, and 16.9%, oral steroids. We can assume that the use of oral 
corticosteroids among LRA patients in the present study was significantly lower, 
since 15.3% of all cases with asthma were HRA. 
4) We had no information on the patients’ smoking habits, as some of the 
associations we found that were at higher risk for IPI (e.g. ARDs and COPD) may 
be confounded by smoking. About half of invasive pneumococcal diseases in 
immunocompetent non-elderly adults were previously attributed to cigarette 
smoking (76). In a previous case-control study of the risk of cigarette smoking on 
the development of IPI (76), asthma was associated with an increased odds ratio of 
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2.5 for IPI before, but not after, adjustment for other risk factors such as smoking 
and socioeconomic status. 
5) Information about the PPV23 vaccination status of the IPI cases was unavailable 
in laboratory-based surveillance. However, PPV23 is little used in Finland. 
Consequently, one can reasonably assume that disease rates in our study population 
represent a pre-vaccination baseline. 
6) Due to the registry-based study design, our analysis of the clinical outcome 
lacked chart review data to assess the effect of the severity of illness indicators on 
IPI-related mortality. Information on some underlying conditions may also have 
been missing. 
7) The denominator data for persons with comorbidities were available only in 
aggregated form and allowed no estimation of age-specific rates in various groups of 
patients with comorbidities. 
8) Data on the numbers of blood and CSF cultures performed at clinical 
microbiology laboratories were available only in aggregate form and allowed no 
evaluation of possible age- and gender-specific differences or of secular trends in 
blood and CSF culturing rates. Clinical practices and protocols for culture sampling 
may differ by age, particularly among the elderly, and may reflect population groups 
at increasing risk (8). 
9) Information about the incidence of and serotypes causing IPI is restricted to the 
years 1995-2002. Some studies have recently reported data reflecting the current 
situation (254). From 2003 to 2006, the incidence of IPI has remained at around 14 
per 100 000 population. During 1995-2006, a seasonal pattern and constancy in the 
composition of majority serotypes has prevailed with the fluctuation in rank order of 
prevalent serotypes among children under two. In other age groups, the proportion 
of PCV7 and PCV10 serotypes has significantly increased.  
 
 6.8 Summary  
The findings of this study establish a baseline for the epidemiological characteristics 
of IPI in Finland and provide new information about developments in the 
epidemiology of IPI. The main results of the study are summarized below. 
I The annual incidence of IPI increased by one-third during the study 
period. Most of this increase stemmed from an increase in pneumococcal 
bacteremia rates. Temporal increases and higher regional IPI rates were 
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significantly associated with higher blood culturing rates. This indicates 
that the true incidence of SPB in Finland may be higher than previously 
estimated, and that blood culture rates should be taken into account when 
evaluating surveillance data and the impact of vaccination programs. 
About 89% and 86% of the serotypes/groups of pneumococcal isolates 
from nonelderly adults and patients aged 65 years and older, respectively, 
were included in PPV23. Some 70%, 48%, and 52% of IPIs among 
children under five, nonelderly adults, and persons aged 65 years and 
older, respectively, resulted from serotypes included in PCV7. The 
serotype coverage of currently available pneumococcal vaccines is high, 
and is even higher with investigational conjugate vaccines. The use of 
pneumococcal vaccines has been suboptimal, thus emphasizing the need 
for comprehensive prevention strategies.    
II The patient groups with the highest rates of IPI differed from those at the 
highest risk of death (e.g., patients with ARDs had a mortality rate similar 
to that of patients with non-hematological malignancies). In addition to 
young children and the elderly, the burden of IPI is also substantial among 
working-age persons without high-risk conditions. In the general 
population of non-elderly adults, two-thirds of invasive infections and 
one-half of fatal cases occur in persons with no recognized PPV23 
indication. The current vaccine indications fail to address a significant 
proportion of the disease burden among nonelderly adults. 
III Data in our study indicate that both HRA and LRA are independent 
risk factors for IPI among nonelderly adults. The risk among persons 
with a recent hospitalization for asthma was 4.4 times as high as 
among those with other chronic pulmonary diseases. About 90% of the 
serotypes of the pneumococcal isolates from patients in this age group 
are included in PPV23, and some 50% in the PCV7, respectively. Not 
only are persons with HRA requiring hospitalization and 
immunosuppressive therapy at significantly increased risk, but so are 
those with LRA. The results of our study support other recently published 
findings that asthma is an independent risk factor for IPI. 
IV About 10% of all SPBs were healthcare-associated, and mortality 
among patients with NPB was more than twice as high as among 
patients with CAPB. Most patients with nosocomial disease had 
underlying conditions for which PPV23 is recommended, thus 
emphasizing the importance of strengthening prevention efforts in 
these patient groups. This is the first time the impact of healthcare-
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associated pneumococcal bacteremia has been quantified from 
nationwide surveillance data. 
6.9 Opportunities for prevention 
Our results confirmed the appropriateness of current PPV23 indications for 
underlying medical conditions while at the same time highlighting multiple missed 
opportunities for their prevention. Because of the considerable disease burden and 
high mortality among nonelderly adults with no current vaccine indication, reaching 
this group of patients through prevention strategies is a priority. 
One proposed strategy includes lowering the recommended age for PPV23 
vaccination to include all persons aged 50 years and older, which could result in a 
moderately higher number of IPI cases prevented than with the current high-risk 
indications (20, 255). However, given the increasing risk for IPI and mortality with 
age, and the unknown duration of protection after primary immunization, the 
optimal timing and frequency of revaccination with PPV23 must be determined 
before this strategy can be implemented. Currently, no data are available on the 
clinical effectiveness of revaccination, and serological studies suggest that antibody 
responses may be lower after revaccination than after primary vaccination (256-
258). Routine childhood immunization with PCV7 remains to be introduced in 
Finland. However, increasing evidence has been accumulating about the substantial 
indirect benefits of childhood PCV7 immunization in reducing rates of adult 
pneumococcal disease in the USA and elsewhere (259, 260). There is also evidence 
from the USA that the all-cause rate for pneumonia has decreased significantly in 
the age-groups under two years and 18-39 years (261-263). The serotypes included 
in PCV7 cause approximately 50% of IPI in Finnish adults, a proportion similar to 
that in the USA before PCV7 introduction. Therefore, introducing routine childhood 
immunization in Finland could provide an opportunity to substantially reduce the 
disease burden among difficult-to-reach groups of working-age adults with no 
PPV23 indications (263).  
Our study supports recently published evidence that asthma is an independent risk 
factor for IPI. Further, PPV23 serotype coverage of IPI cases aged 18-49 years with 
chronic pulmonary disease, mainly asthma, was about 90%. We recommend that 
asthma be considered for inclusion in the list of conditions for which PPV23 is 
recommended to prevent IPI and community-acquired pneumonia (264, 265).    
Because a substantial proportion of NPB in Finland stems from conjugate vaccine 
serotypes, a childhood immunization program could also offer the potential to 
reduce NPB indirectly. Targeting persons with chronic conditions for the 
  71
administration of PPV23 remains an established strategy for reaching those at 
highest risk for invasive infection.   
An additional prevention strategy addressing this major public health problem would 
be campaigns and other actions aimed at reducing cigarette smoking. A case control 
study from the USA (188) estimated that if the prevalence of cigarette smoking 
could be reduced from 25% to 15%, the incidence of IPI among nonelderly adults 
would potentially decrease by approximately 18%.  
Heavy alcohol use is also a distinct risk factor for IPI, and its mortality rate is 
significant. Political decisions aimed at reducing total alcohol consumption in 
society, as well as campaigns targeting alcoholics with PPV23, could reduce the 
burden of IPI in this patient group. Raising clinical awareness of IPI among 
alcoholics in order to improve both diagnostics and treatment is also important. 
6.10 Future directions 
Although PPV23 is an established tool in the prevention of IPI in adults, this vaccine 
has several limitations, such as poor antibody responses in immunocompromized 
persons, limited duration of protection – especially among the elderly, poor 
immunogenicity of several antigens, and the lack of impact on pneumococcal 
carriage. Because the aging population and the growing number of persons at greater 
risk for IPI due to immunosuppressive medication increases the public health impact 
of IPI, the demand for more efficient prevention strategies is considerable. 
Following the introduction of PCV7 in the USA, population-based data have shown 
not only a large, rapid decline in overall and vaccine-type IPI in children under two 
years, but also reductions in vaccine-type disease among unvaccinated children and 
adults, as well as drops in the frequency of antibiotic-resistant infections (266). In 
Finland, public health authorities are preparing for the introduction of routine 
childhood immunization with pneumococcal conjugate vaccines, which is likely to 
occur in 2010 (267). Estimates indicate that the introduction of routine childhood 
immunization with PCV7 would prevent 3 cases of meningitis, 80 cases of 
pneumococcal bacteremia, 190 cases of pneumonia, 9600 cases of acute otitis 
media, and 1.2 deaths annually among children under five. Considering the indirect 
effects of the vaccine in the population of adults and children under five and 
calculating with a herd effect of 20%, an additional 100 cases of IPI and 19 deaths 
would be prevented. Postulating that PCV7 reduces in-patient pneumonia cases by 
4%, 800 cases of pneumococcal pneumonia and 5 pneumonia-related deaths could 
be prevented among those over five.  
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New conjugate vaccines that will incorporate additional serotypes are in 
development, but this is probably no long-term solution to the replacement of 
vaccine serotypes. A vaccine based on pneumococcal proteins common to all 
serotypes and that contributes to pathogenesis is the current topic of interest among 
vaccine experts (226). The most promising and well-characterized vaccine 
candidates are pneumolysin, PspA, and PspC. Preliminary animal studies have 
demonstrated their potential to protect against infection with multiple serotypes or to 
prevent nasopharyngeal carriage or both (268, 269). 
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9 APPENDIX 
 
Appendix 1. Recommendations for the use of 23-valent pneumococcal 
polysaccharide vaccine in Finland  
Immunocompetent persons aged ≥ 5 years 
• Persons with cardiac failure, chronic pulmonary disease (chronic obstructive 
pulmonary disease, emphysema, but not asthma), diabetes mellitus, liver failure, 
renal failure, cerebrospinal fluid leakage, cochlear implants, and alcoholism 
• Persons aged ≥ 65 years 
• Persons residing in long-term care facilities 
Immunocompromised persons aged ≥ 5 years 
• Persons with functional or anatomic asplenia, HIV infection, lymphoma, multiple 
myeloma, nephrotic syndrome, congenital or acquired immunodeficiency (not 
agammaglobulinemia) 
• Persons who received an organ or bone-marrow transplant 
• Persons undergoing ongoing immunosuppressive chemotherapy (including 
systemic corticosteroids) 
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